1. Introduction {#sec1-life-10-00094}
===============

Knee disorders are among the most frequent disorders treated by orthopedic surgeons. Traumatic knee injuries, as well as knee degeneration, require special attention and appropriate treatment. The first line of treatment is usually conservative and includes physical therapy, rehabilitation, braces or non-steroid inflammatory drugs. Recently, orthobiologics---naturally occurring substances in the body---were introduced to clinics \[[@B1-life-10-00094],[@B2-life-10-00094]\]. One type of orthobiologic substance, platelet-rich plasma (PRP) shows promising results for minimally invasive treatment of knee lesions through enhanced healing potential of damaged cartilage, tendons, and ligaments \[[@B1-life-10-00094]\]. PRP, also known as platelet-rich fibrin (PRF), platelet concentrate or platelet-rich growth factors (PRGFs) is a concentration of platelets derived from the patient's whole blood, which has to be centrifuged to obtain a ready-to-use product \[[@B2-life-10-00094],[@B3-life-10-00094]\]. The mechanism of action relies on releasing cytokines and growth factors from alpha granules such as interleukin 1β, interleukin 8, tumor necrosis factor (TNF-α), platelet derived growth factor (PDGF), platelet derived endothelial growth factor (PDEGF), transforming growth factor β1 (TGF-β1), insulin-like growth factor 1 (IGF-1), fibroblast growth factor 2 (FGF-2), hepatocyte growth factor (HGF), and vascular endothelial growth factor A (VEGF-A). These enhance healing by stimulating cell proliferation, migration, and differentiation, alongside interaction with the immune system, inflammation, and angiogenesis \[[@B1-life-10-00094],[@B2-life-10-00094],[@B3-life-10-00094],[@B4-life-10-00094]\]. Possible indications for PRP application in knee disorders and knee surgery are cartilage degeneration in osteoarthritis and soft tissue injuries in sports medicine. Well documented clinical trials are related to patients with degenerative meniscus lesions, patellar tendinopathy, graft remodeling in anterior cruciate ligament (ACL) reconstruction, hamstring tendinopathy, and medial collateral ligament (MCL) injuries \[[@B1-life-10-00094],[@B5-life-10-00094]\]. There is also some evidence for pain reduction after total knee arthroplasty (TKA) and bone remodeling after osteotomies. Several systematic reviews and meta-analyses have been published, although with contradictory results; therefore, we aimed to elucidate these controversial issues and performed a systematic review and meta-analysis on the efficacy of PRP use in disorders around the knee.

2. Results {#sec2-life-10-00094}
==========

2.1. Literature Search {#sec2dot1-life-10-00094}
----------------------

A literature search through electronic databases identified a total of 4002 records according to the selected search algorithm and two additional studies were included through reference list evaluation. A total of 3645 citations was excluded as irrelevant according to title and/or abstract. The abstracts of 357 remaining articles were assessed for eligibility. From these, 274 were excluded. The remaining 83 clinical studies published between 2005 and 2020 with 5323 patients were included in this review. The literature search flowchart is shown in [Figure 1](#life-10-00094-f001){ref-type="fig"}.

2.2. Study Characteristics {#sec2dot2-life-10-00094}
--------------------------

A total of 83 randomized controlled trials (RCTs) and seven non-RCTs was included in our study. The characteristics of the selected articles are summarized in [Table 1](#life-10-00094-t001){ref-type="table"}, [Table 2](#life-10-00094-t002){ref-type="table"}, [Table 3](#life-10-00094-t003){ref-type="table"}, [Table 4](#life-10-00094-t004){ref-type="table"}, [Table 5](#life-10-00094-t005){ref-type="table"}, [Table 6](#life-10-00094-t006){ref-type="table"}, [Table 7](#life-10-00094-t007){ref-type="table"}, [Table 8](#life-10-00094-t008){ref-type="table"} and [Table 9](#life-10-00094-t009){ref-type="table"}. All of the selected studies were included into a systematic review. Mean follow-up period was 12 months (ranging from 10 days to 3 years) and the mean number of patients included was 62 (ranging from 20 to 315).

One injection of platelet-rich plasma was performed in 55 studies, two injections in 14 studies, three injections in 21 studies and four injections in two studies. Platelet concentration was provided in 48 articles, 33 studies used leukocyte-rich PRP, 25 studies used leukocyte-poor PRP, and in 25 studies no information was provided.

In addition, 41 studies compared the application of PRP versus other treatments (25 versus hyaluronic acid (HA), 4 versus corticosteroids, 4 versus microfractures, 10 versus other substances), 42 studies compared the use of PRP versus placebo (12 versus saline and 30 versus no injection), and 7 studies compared single injection of PRP versus multiple injections. Primary outcomes included pain measurement (visual analog scale (VAS)) in 48 studies and functional outcomes in 73 studies: International Knee Documentation Committee (IKDC), 24 studies; Western Ontario and McMaster Universities Osteoarthritis Index (WOMAC), 32; Victorian Institute of Sport Assessment for patella tendonitis (VISA-P), 5; 36-Item Short Form Survey (SF-36), 7; Knee injury and Osteoarthritis Outcome Score (KOOS), 12; The Lysholm Knee Scoring Scale, 14; Teger Activity Score, 10; Lequesne score, 6; and others (meniscal repair failure, 6; time for return to sport (RTS), 4; re-injury, 3; knee stability, 6; graft integration, 5; tunnel widening, 4; hemoglobin drop, 6; range of movement (ROM), 9). Radiographic outcomes were presented in 15 studies (computed tomography, X-ray, magnetic resonance imaging, ultrasonography).

A total of 75 studies was included into quantitative synthesis: VAS was analyzed in 5 subgroups, IKDC, 5; WOMAC, 3; Tegner, 1; KOOS (activities of daily living (ADL), 1; pain, 1; quality of life (QoL), 1; sport, 1; symptoms, 1); VISA-P, 1; SF-36, 1; graft integration, 1; tunnel widening, 1; re-injury rate, 1; RTS, 1; repair failure, 1; blood loss, 1; KT-1000 (knee arthrometer), 1; adverse events, 1.

2.3. Patellar Tendinitis (PT) {#sec2dot3-life-10-00094}
-----------------------------

Four studies reported data from 137 patients. Inclusion criteria required randomization, control groups, use of VAS for pain as well as VISA-P with a minimum of 6 months follow-up. We included RCTs comparing the use of PRP in patellar tendinopathy versus saline, dry needling (DN) or extracorporeal shockwave therapy (ESWT) ([Table 1](#life-10-00094-t001){ref-type="table"}).

Two studies showed non-significant differences in favor of PRP (*p* \> 0.05) in VAS comparing PRP with saline injection after 1 year \[[@B6-life-10-00094]\] or DN after 6 months \[[@B7-life-10-00094]\]. Two studies also reported pain scales (VAS) with significant differences at, respectively, 1 year compared to ESWT (*p* = 0.009) \[[@B8-life-10-00094]\] and 6 months compared to high volume image guided injections (HVIGIs) \[[@B9-life-10-00094]\]. The pooled estimate for these 4 studies demonstrated non-significant differences in favor of PRP (*p* = 0.80) ([Figure 2](#life-10-00094-f002){ref-type="fig"}A).

The same authors measured the severity of jumper's knee via VISA-P score. Two studies \[[@B6-life-10-00094],[@B7-life-10-00094]\] proved no differences in symptom severity after 6 months and 1 year with statistical significance greater than 0.05. Another study showed significant differences between groups of PRP injection and ESWT (*p* = 0.026) after 1 year \[[@B8-life-10-00094]\] and significant differences as compared to HVIGI (*p* = 0.03) \[[@B9-life-10-00094]\]. Pooled data estimated for these studies demonstrated non-significant differences in favor of PRP (*p* = 0.93) ([Figure 2](#life-10-00094-f002){ref-type="fig"}B).

Functional outcomes with Tegner, Lysholm, and SF-12 scores were analyzed in one study. Dry needling showed significant improvement at \>26 weeks when compared to PRP group (*p* = 0.006) \[[@B7-life-10-00094]\]. In another study, a modified Blazina scale showed significant improvement at 12 months in favor of the PRP group (*p* = 0.015) \[[@B8-life-10-00094]\].

Two studies were at high risk of bias for one or more domains \[[@B6-life-10-00094],[@B8-life-10-00094]\], and two studies were at an unclear risk of bias for one or more domains ([Figure 2](#life-10-00094-f002){ref-type="fig"}C). Moderate risk of performance bias was identified in two studies \[[@B6-life-10-00094],[@B8-life-10-00094]\]. Similarly, two were at risk of detection bias \[[@B6-life-10-00094],[@B7-life-10-00094]\]. No data concerning the generation of random sequence and allocation were provided thus increasing risk of selection bias \[[@B9-life-10-00094]\].

2.4. Muscle Injuries around the Knee {#sec2dot4-life-10-00094}
------------------------------------

Four studies including 224 patients measured time for return to sport after a muscle injury (hamstring, quadriceps, gastrocnemius). In all reported studies PRP was delivered intralesionally. Two studies performed the injection under the guidance of ultrasound \[[@B10-life-10-00094],[@B11-life-10-00094]\] and the other two used magnetic resonance imaging (MRI) prior to the injection to detect the damaged area \[[@B12-life-10-00094],[@B13-life-10-00094]\]. Three studies reported re-injury incidences, and only two provided patient reported outcome measures (pain). Each study compared rehabilitation programs with/without PRP injection. All reported shorter time for return to sport in favor of PRP in comparison to control groups ([Table 2](#life-10-00094-t002){ref-type="table"}). One study included only professional athletes \[[@B12-life-10-00094]\] and three studies recruited both competitive and recreational athletes \[[@B10-life-10-00094],[@B11-life-10-00094],[@B13-life-10-00094]\].

The mean time for return to sport ranged from 21 to 43 days in the PRP group and from 25 to 45 days in the control groups. Two studies \[[@B10-life-10-00094],[@B11-life-10-00094]\] showed significant differences in RTS (*p* = 0.001; *p* = 0.02) and two studies \[[@B12-life-10-00094],[@B13-life-10-00094]\] showed shorter RTS, but no significant differences between PRP and control groups (*p* \> 0.05). The pooled estimate for these 4 studies demonstrated significant differences in favor of PRP (*p* ≤ 0.00001) with a mean difference of −4.16 (−5.44, −2.88) ([Figure 3](#life-10-00094-f003){ref-type="fig"}A). Due to the high heterogeneity of patient recruitment and only small differences in the time to return to sport, an analysis of cost-effectiveness should be accomplished to evaluate whether the results are worth the cost.

The re-injury rate ranged from 6% to 27% in the PRP group and from 10% to 31% in the control groups. Three studies \[[@B10-life-10-00094],[@B12-life-10-00094],[@B13-life-10-00094]\] reported lower re-injury rate in favor of the PRP group but with non-significant differences (*p* = 0.47) ([Figure 3](#life-10-00094-f003){ref-type="fig"}B).

Two studies \[[@B10-life-10-00094],[@B11-life-10-00094]\] showed significantly lower pain severity (beta regression coefficient = −0.272, 95% confidence interval (CI) (−0.5, −0.045), *p* = 0.019 during motion and −0.390, 95% CI (−0.67, −0.11), *p* = 0.007, respectively) but non-significant differences in pain intensity (*p* = 0.157) \[[@B13-life-10-00094]\].

Two studies were at high risk of bias for two domains, and two studies were at high risk for one domain ([Figure 3](#life-10-00094-f003){ref-type="fig"}C). Moderate risk of performance bias was identified in three studies \[[@B10-life-10-00094],[@B11-life-10-00094],[@B12-life-10-00094]\]. One was at risk of reporting bias \[[@B11-life-10-00094]\]. Discrepancies between the number of patients undergoing final follow up in Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) chart versus manuscript was detected in two studies \[[@B10-life-10-00094],[@B13-life-10-00094]\].

2.5. High Tibial Osteotomy (HTO) {#sec2dot5-life-10-00094}
--------------------------------

Two RCTs including 80 patients evaluated the intraoperative use of PRP as an adjunct to HTO with or without the addition of other myeloid stromal cells \[[@B14-life-10-00094],[@B15-life-10-00094]\] ([Table 3](#life-10-00094-t003){ref-type="table"}).

Koh et al. injected PRP into the medial joint space under arthroscopic visualization and afterwards performed HTO. This study showed significant differences in KOOS and VAS in favor of PRP with the addition of Mesenchymal Stem Cells (MSC) in a 2-year follow up (*p* \< 0.05). Second-look arthroscopy during plate removal reported a significant difference between the groups with respect to cartilage healing again in the PRP + MSC groups (*p* = 0.023) \[[@B14-life-10-00094]\].

Dallari et al. added lyophilized bone chips with platelet gel and with/without bone marrow (BM) to the osteotomy hole. This study showed better osseointegration in X-ray analysis after 1-year follow up and histologically more active osteogenic processes in favor of PRP+/−BM groups (*p* \< 0.05) \[[@B15-life-10-00094]\].

Both studies were at high risk of bias for one domain (performance bias).

2.6. Total Knee Arthroplasty (TKA) {#sec2dot6-life-10-00094}
----------------------------------

Six RCT studies including 621 patients evaluated the use of PRP as an adjunct to TKA ([Table 4](#life-10-00094-t004){ref-type="table"}). All studies applied PRP intraoperatively: three sprayed platelet gel onto the exposed surface of the wound \[[@B16-life-10-00094],[@B17-life-10-00094],[@B18-life-10-00094]\] and the other three injected PRP into the joint \[[@B19-life-10-00094],[@B20-life-10-00094],[@B21-life-10-00094]\]. The aim of all these studies was to assess potential blood loss during the procedure after TKA.

Lower hemoglobin drop was reported in all six studies \[[@B16-life-10-00094],[@B17-life-10-00094],[@B18-life-10-00094],[@B19-life-10-00094],[@B20-life-10-00094],[@B21-life-10-00094]\] with significant differences and two studies reported lower calculated blood loss in the PRP group (*p* \> 0.05; *p* \< 0.001) \[[@B17-life-10-00094],[@B21-life-10-00094]\]. There were significant differences in favor of PRP in comparison to the control groups for the overall effect on blood parameters (standardized mean difference −0.29, 95% CI (−0.46, −0.11), *p* = 0.001) for the pooled estimates for all six studies ([Figure 4](#life-10-00094-f004){ref-type="fig"}A).

Four studies reported better pain control in the PRP group (VAS) for a short time period after surgery \[[@B16-life-10-00094],[@B18-life-10-00094],[@B19-life-10-00094],[@B20-life-10-00094]\]. No effect was observed in long-term follow-up.

Functional outcome was measured using the WOMAC \[[@B18-life-10-00094],[@B19-life-10-00094],[@B20-life-10-00094]\] score in three studies and Knee Society Score (KSS) and KOOS in another study \[[@B17-life-10-00094]\], but with non-significant differences between the groups. Range of motion was measured in all studies with non-significant differences between the groups \[[@B16-life-10-00094],[@B17-life-10-00094],[@B18-life-10-00094],[@B19-life-10-00094],[@B20-life-10-00094],[@B21-life-10-00094]\]. Thromboembolism was absent in all studies. However, Morishita et al. reported one patient requiring a secondary skin suture in the PRP group \[[@B17-life-10-00094]\]. Peerbooms et al. and Guereirro et al. reported superficial wound infection in one and two patients, respectively, all treated successfully with antibiotics \[[@B18-life-10-00094],[@B19-life-10-00094]\]. A subsequent study performed by Guerreiro reported two cases of deep infection treated by debridement and TKA review \[[@B20-life-10-00094]\].

Two studies were at high risk of bias for one domain ([Figure 4](#life-10-00094-f004){ref-type="fig"}B). Low risk of performance bias was identified in four studies \[[@B16-life-10-00094],[@B17-life-10-00094],[@B19-life-10-00094],[@B20-life-10-00094]\]. A moderate risk of performance bias was identified in two studies \[[@B18-life-10-00094],[@B21-life-10-00094]\] ([Figure 4](#life-10-00094-f004){ref-type="fig"}B).

2.7. Arthroscopy {#sec2dot7-life-10-00094}
----------------

Four RCTs \[[@B22-life-10-00094],[@B23-life-10-00094],[@B24-life-10-00094],[@B25-life-10-00094],[@B26-life-10-00094],[@B27-life-10-00094]\] and three prospective cohort \[[@B26-life-10-00094],[@B27-life-10-00094],[@B28-life-10-00094]\] studies, including 199 patients, evaluated the use of PRP as an adjunct to knee arthroscopy treatment for cartilage and/or meniscal pathology: two studies included patients with osteoarthritis (OA) changes according to the Kellgren and Lawrence (KL) classification system with concomitant meniscal lesions \[[@B22-life-10-00094],[@B23-life-10-00094]\]; two studies included patients with cartilage lesions of grade III--IV according to the Outerbridge classification system and early OA stages I--II according to the KL classification system \[[@B24-life-10-00094],[@B27-life-10-00094]\]; one study included patients with chondral defects of medial femoral condyle grade II--III according to the Outerbridge classification system \[[@B25-life-10-00094]\]; and one study included patients with OA stage II--III according to the KL classification system \[[@B26-life-10-00094]\]. In five studies \[[@B23-life-10-00094],[@B24-life-10-00094],[@B26-life-10-00094],[@B27-life-10-00094],[@B28-life-10-00094]\] PRP was used intraoperatively, and in another two studies PRP was used after surgery \[[@B22-life-10-00094],[@B25-life-10-00094]\]. Kim et al. was excluded from the meta-analysis. The study analyzed PRP effectiveness when applied as an adjuvant to injection of MSC versus surgical implantation of MSCs \[[@B28-life-10-00094]\].

Two studies reported functional outcome in the WOMAC score \[[@B22-life-10-00094],[@B26-life-10-00094]\]. One of them (RCT) showed significant differences in WOMAC scores (*p* = 0.0002) when comparing PRP to a control group at 18 months and reported hyaluronic acid injections to be more effective than PRP \[[@B22-life-10-00094]\]. The pooled estimate for these two studies showed significant differences in favor of the PRP group (*p* = 0.0040, [Figure 5](#life-10-00094-f005){ref-type="fig"}A). Four studies \[[@B24-life-10-00094],[@B25-life-10-00094],[@B27-life-10-00094],[@B28-life-10-00094]\] reporting outcomes measured in IKDC ([Figure 5](#life-10-00094-f005){ref-type="fig"}B), showed significant differences in favor of PRP (*p* \< 0.00001). In subgroup analysis, two RCTs presented significant differences in favor of PRP when applied with microfractures \[[@B24-life-10-00094],[@B25-life-10-00094]\]. Additionally, one prospective cohort trial also showed significant differences in favor of PRP \[[@B27-life-10-00094]\]. Another two studies \[[@B23-life-10-00094],[@B27-life-10-00094]\] showed better outcomes in patient self-assessment SF-36 scale, one of them in favor of the control \[[@B27-life-10-00094]\] and the other in favor of the PRP group \[[@B23-life-10-00094]\]; but differences were not significant (*p* = 0.81, [Figure 5](#life-10-00094-f005){ref-type="fig"}C). Functional outcome was also measured by the Lysholm score by three studies \[[@B23-life-10-00094],[@B24-life-10-00094],[@B26-life-10-00094]\] ([Figure 5](#life-10-00094-f005){ref-type="fig"}D), showing non-significant differences in favor of PRP (*p* = 0.03).

Three randomized studies \[[@B23-life-10-00094],[@B24-life-10-00094],[@B25-life-10-00094]\] and two prospective cohort studies \[[@B26-life-10-00094],[@B27-life-10-00094]\] used VAS to assess pain level. Two studies \[[@B24-life-10-00094],[@B25-life-10-00094]\] with the addition of PRP to arthroscopic microfractures showed significant differences in pain severity in favor of PRP (*p* \< 0.0001); although two cohort studies report non-significant differences in favor of PRP (*p* = 0.81). Arthroscopy without microfractures showed lower pain levels when complemented with PRP, but the differences were not significant (*p* = 0.07) \[[@B23-life-10-00094]\]. The pooled estimate for these five studies demonstrated non-significant differences in favor of the PRP group (*p* = 0.13) ([Figure 6](#life-10-00094-f006){ref-type="fig"}A). Due to the large variety of patient recruitment regimens, any conclusions should be stated carefully. However, all subgroups showed positive effects of PRP during synthesis. There is a need for more RCTs to allow for definitive conclusions with low heterogeneity.

Two studies were at high risk of bias for four domains \[[@B26-life-10-00094],[@B27-life-10-00094]\] and three studies were at high risk of bias for one domain \[[@B23-life-10-00094],[@B25-life-10-00094],[@B28-life-10-00094]\]. High risk of performance bias was identified in two studies \[[@B26-life-10-00094],[@B27-life-10-00094]\], moderate risk of performance bias was identified in three studies \[[@B23-life-10-00094],[@B25-life-10-00094],[@B28-life-10-00094]\], and a low risk of performance bias was identified in two studies \[[@B22-life-10-00094],[@B24-life-10-00094]\] ([Figure 6](#life-10-00094-f006){ref-type="fig"}B).

2.8. Anterior Cruciate Ligament Reconstruction (ACL) {#sec2dot8-life-10-00094}
----------------------------------------------------

Sixteen RCTs, including 740 patients, evaluated the use of PRP as an adjunct to ACL reconstruction with patellar ligament (Bone-Patella Tendon-Bone-BPTB) autograft \[[@B29-life-10-00094],[@B30-life-10-00094],[@B31-life-10-00094],[@B32-life-10-00094],[@B33-life-10-00094],[@B34-life-10-00094],[@B35-life-10-00094]\] or hamstrings graft \[[@B33-life-10-00094],[@B36-life-10-00094],[@B37-life-10-00094],[@B38-life-10-00094],[@B39-life-10-00094],[@B40-life-10-00094],[@B41-life-10-00094],[@B42-life-10-00094],[@B43-life-10-00094],[@B44-life-10-00094]\] ([Table 6](#life-10-00094-t006){ref-type="table"}).

Five studies reported pain assessment with the VAS \[[@B29-life-10-00094],[@B30-life-10-00094],[@B31-life-10-00094],[@B32-life-10-00094],[@B34-life-10-00094]\]. The overall effect showed no significant differences with respect to pain (*p* = 0.43); however, two studies showed significant differences in short-term follow-up in favor of the PRP group (2--6 months) \[[@B31-life-10-00094],[@B32-life-10-00094]\] ([Figure 7](#life-10-00094-f007){ref-type="fig"}A).

Seven studies reported functional results via IKDC scores \[[@B30-life-10-00094],[@B32-life-10-00094],[@B34-life-10-00094],[@B38-life-10-00094],[@B39-life-10-00094],[@B43-life-10-00094],[@B44-life-10-00094]\], but only four of them provided data allowing for synthesis \[[@B30-life-10-00094],[@B32-life-10-00094],[@B43-life-10-00094],[@B44-life-10-00094]\] ([Figure 7](#life-10-00094-f007){ref-type="fig"}B) and no significant differences (*p* = 0.83) were detected. A further four studies provided only categorical output data (excellent, good, regular, poor) with non-significant odds ratio (1.39 (0.27, 7.21), *p* = 0.7). Functional outcome was measured by the Lysholm score in four studies and provided insignificant results (*p* = 0.19, [Figure 7](#life-10-00094-f007){ref-type="fig"}C). Five studies used the Tegner scale for activity assessment \[[@B38-life-10-00094],[@B42-life-10-00094],[@B43-life-10-00094],[@B44-life-10-00094],[@B45-life-10-00094]\]. Pooled estimates for these studies showed no significant differences (*p* = 0.38) in favor of the control ([Figure 7](#life-10-00094-f007){ref-type="fig"}D). Three studies showed no significant differences \[[@B38-life-10-00094],[@B42-life-10-00094],[@B43-life-10-00094]\] in functional outcomes, one study did not report functional outcome results \[[@B42-life-10-00094]\], and one study reported worse outcomes in both groups when compared to baseline \[[@B32-life-10-00094]\].

Six studies reported the outcomes of anterior tibial translation assessments \[[@B34-life-10-00094],[@B38-life-10-00094],[@B41-life-10-00094],[@B42-life-10-00094],[@B43-life-10-00094],[@B44-life-10-00094]\] with no significant differences between groups (*p* = 0.18) in meta-analysis. Only one study showed a significant difference in favor of PRP using KT-1000 ([Figure 8](#life-10-00094-f008){ref-type="fig"}) \[[@B41-life-10-00094]\].

Five studies reported the outcome of tunnel widening after graft fixation, two of them used computer tomography (CT) \[[@B43-life-10-00094],[@B44-life-10-00094]\] and three used MRI \[[@B39-life-10-00094],[@B41-life-10-00094],[@B42-life-10-00094]\] to evaluate tunnel enlargement. The pooled estimates for four studies included in meta-analyses showed non-significant differences in favor of the control (*p* = 0.54) ([Figure 8](#life-10-00094-f008){ref-type="fig"}).

Eight studies assessed the outcomes of ACL graft integration in the femoral or tibial tunnel. Six of them evaluated signal intensity of the graft on MRI \[[@B33-life-10-00094],[@B34-life-10-00094],[@B35-life-10-00094],[@B36-life-10-00094],[@B37-life-10-00094],[@B39-life-10-00094]\], one reported significant difference in ACL density measured on CT (*p* \< 0,01) \[[@B38-life-10-00094]\], and one explored better remodeling using histologic parameters (*p* = 0.024) \[[@B40-life-10-00094]\]. Three studies \[[@B33-life-10-00094],[@B39-life-10-00094],[@B40-life-10-00094]\] reported faster graft remodeling (*p* \< 0.001; *p* = 0,036; *p* = 0.024), and the remaining four \[[@B34-life-10-00094],[@B35-life-10-00094],[@B36-life-10-00094],[@B37-life-10-00094]\] showed no significant differences during the final follow-up. We included in the meta-analysis four studies \[[@B35-life-10-00094],[@B36-life-10-00094],[@B39-life-10-00094],[@B40-life-10-00094]\] and the pooled estimates for these studies showed non-significant differences in favor of PRP (*p* = 0.06).

Three studies were at high risk of bias for two domains \[[@B36-life-10-00094],[@B39-life-10-00094],[@B43-life-10-00094]\], eight studies were at high risk of bias for one domain \[[@B30-life-10-00094],[@B32-life-10-00094],[@B33-life-10-00094],[@B34-life-10-00094],[@B35-life-10-00094],[@B40-life-10-00094],[@B42-life-10-00094],[@B44-life-10-00094]\], and one study was at high risk of bias for two domains with a risk of reporting bias for one domain \[[@B38-life-10-00094]\]. High risk of performance bias was identified in one study \[[@B38-life-10-00094]\], a moderate risk of performance bias was identified in twelve studies \[[@B30-life-10-00094],[@B32-life-10-00094],[@B33-life-10-00094],[@B34-life-10-00094],[@B35-life-10-00094],[@B36-life-10-00094],[@B39-life-10-00094],[@B40-life-10-00094],[@B42-life-10-00094],[@B43-life-10-00094],[@B44-life-10-00094],[@B46-life-10-00094]\], and a low risk of performance bias was identified in three studies \[[@B29-life-10-00094],[@B31-life-10-00094],[@B41-life-10-00094]\] .

2.9. Meniscal Repair {#sec2dot9-life-10-00094}
--------------------

Two RCTs \[[@B47-life-10-00094],[@B48-life-10-00094]\] and five non-randomized studies \[[@B49-life-10-00094],[@B50-life-10-00094],[@B51-life-10-00094],[@B52-life-10-00094],[@B53-life-10-00094]\] evaluated the use of PRP in meniscus healing. In five studies, PRP was injected after arthroscopic meniscus repair \[[@B47-life-10-00094],[@B49-life-10-00094],[@B50-life-10-00094],[@B52-life-10-00094],[@B53-life-10-00094]\], in one study patients underwent open meniscal repair with an adjunct of PRP \[[@B51-life-10-00094]\], and in another the authors compared percutaneous meniscal trephination with or without PRP \[[@B6-life-10-00094]\].

Six studies reported failure rates of meniscus healing, two randomized studies using MRI and second-look arthroscopy showed significant differences in favor of PRP (*p* = 0.006) \[[@B47-life-10-00094],[@B48-life-10-00094]\], and another four non-randomized studies also showed significant differences in favor of PRP (*p* = 0.02) \[[@B50-life-10-00094],[@B51-life-10-00094],[@B52-life-10-00094],[@B53-life-10-00094]\]. In three studies the failure rate was defined by the need for revision surgery \[[@B50-life-10-00094],[@B52-life-10-00094],[@B53-life-10-00094]\] and in the final study, MRI was used to assess meniscus healing \[[@B51-life-10-00094]\]. One study did not provide any objective radiographic outcomes, only commenting "some" MRIs \[[@B49-life-10-00094]\]. The pooled estimates for all six studies showed significant differences in favor of PRP (*p* = 0.0003), but due to the diversity of clinical trial types, synthesis provided only level of evidence III type data (retrospective cohort studies) with low heterogeneity (I^2^ 12%) ([Figure 9](#life-10-00094-f009){ref-type="fig"}A). Only one study reported outcomes after meniscus repair with concomitant ACLR, and the authors concluded that PRP healing effect depended upon the ACLR \[[@B52-life-10-00094]\].

Five studies \[[@B47-life-10-00094],[@B48-life-10-00094],[@B49-life-10-00094],[@B50-life-10-00094],[@B51-life-10-00094]\] reported functional results via IKDC scores; the pooled estimates for these studies showed non-significant differences in favor of the control (*p* = 0.98), although two randomized trials \[[@B5-life-10-00094],[@B6-life-10-00094]\] showed non-significant differences in favor of PRP (*p* = 0.48) ([Figure 9](#life-10-00094-f009){ref-type="fig"}B).

Functional outcome was also recorded by the Lysholm score in three studies \[[@B49-life-10-00094],[@B50-life-10-00094],[@B53-life-10-00094]\], by the KOOS score in three studies \[[@B47-life-10-00094],[@B48-life-10-00094],[@B51-life-10-00094]\], and by the Tegner score in two studies \[[@B49-life-10-00094],[@B50-life-10-00094]\].

Unfortunately, there is a large variety of clinical trial designs in this section, which may introduce a higher percentage of heterogeneity. Additionally, there could be an increase in heterogeneity via the study of Kaminski et al. \[[@B47-life-10-00094]\] as the final assessment was made by two different methods. There is a strong need for more RCTs allowing for the performance of meta-analysis with low heterogeneity.

One study was at high risk of bias for five domains \[[@B51-life-10-00094]\], four studies were at high risk of bias for four domains \[[@B49-life-10-00094],[@B50-life-10-00094],[@B52-life-10-00094],[@B53-life-10-00094]\], and two studies were at high risk of bias for two domains \[[@B47-life-10-00094],[@B48-life-10-00094]\]. High risk of performance bias was identified in five studies \[[@B49-life-10-00094],[@B50-life-10-00094],[@B51-life-10-00094],[@B52-life-10-00094],[@B53-life-10-00094]\] and moderate risk of performance bias was identified in two studies \[[@B47-life-10-00094],[@B48-life-10-00094]\] ([Figure 9](#life-10-00094-f009){ref-type="fig"}C).

2.10. Osteoarthritis {#sec2dot10-life-10-00094}
--------------------

Thirty-eight studies, including 2962 patients, evaluated the use of PRP in osteoarthritis treatment. Thirty-three articles included patients with Kellgren--Laurence radiographic classifications system \[[@B54-life-10-00094],[@B55-life-10-00094],[@B56-life-10-00094],[@B57-life-10-00094],[@B58-life-10-00094],[@B59-life-10-00094],[@B60-life-10-00094],[@B61-life-10-00094],[@B62-life-10-00094],[@B63-life-10-00094],[@B64-life-10-00094],[@B65-life-10-00094],[@B66-life-10-00094],[@B67-life-10-00094],[@B68-life-10-00094],[@B69-life-10-00094],[@B70-life-10-00094],[@B71-life-10-00094],[@B72-life-10-00094],[@B73-life-10-00094],[@B74-life-10-00094],[@B75-life-10-00094],[@B76-life-10-00094],[@B77-life-10-00094],[@B78-life-10-00094],[@B79-life-10-00094],[@B80-life-10-00094],[@B81-life-10-00094],[@B82-life-10-00094],[@B83-life-10-00094],[@B84-life-10-00094],[@B85-life-10-00094]\], five studies included patients with Ahlbäck radiographic classification system \[[@B86-life-10-00094],[@B87-life-10-00094],[@B88-life-10-00094],[@B89-life-10-00094],[@B90-life-10-00094]\], and one study did not specify the osteoarthritis grade \[[@B91-life-10-00094]\] ([Table 8](#life-10-00094-t008){ref-type="table"} and [Table 9](#life-10-00094-t009){ref-type="table"}). Follow-up ranged from 6 months up to 2 years; thus, for such a large group as OA, heterogeneity will be too high due to our inability to compare outcomes at the same time point.

Twenty-eight studies compared PRP versus control groups \[[@B54-life-10-00094],[@B55-life-10-00094],[@B56-life-10-00094],[@B57-life-10-00094],[@B58-life-10-00094],[@B59-life-10-00094],[@B60-life-10-00094],[@B61-life-10-00094],[@B62-life-10-00094],[@B63-life-10-00094],[@B64-life-10-00094],[@B65-life-10-00094],[@B66-life-10-00094],[@B67-life-10-00094],[@B68-life-10-00094],[@B69-life-10-00094],[@B73-life-10-00094],[@B76-life-10-00094],[@B77-life-10-00094],[@B78-life-10-00094],[@B79-life-10-00094],[@B82-life-10-00094],[@B83-life-10-00094],[@B86-life-10-00094],[@B87-life-10-00094],[@B88-life-10-00094],[@B89-life-10-00094],[@B91-life-10-00094]\], five studies compared PRP with the addition of another substance (MSC or HA) versus the control groups \[[@B74-life-10-00094],[@B79-life-10-00094],[@B81-life-10-00094],[@B91-life-10-00094]\], six studies compared multiple injections of PRP \[[@B54-life-10-00094],[@B59-life-10-00094],[@B80-life-10-00094],[@B85-life-10-00094],[@B86-life-10-00094],[@B87-life-10-00094]\], three studies compared PRGF-Endoret versus control groups \[[@B71-life-10-00094],[@B75-life-10-00094],[@B90-life-10-00094]\], two studies compared autologous conditioned plasma (ACP) versus control groups \[[@B72-life-10-00094],[@B84-life-10-00094]\], and one study compared intraosseous injection versus intra-articular injection versus the control group \[[@B67-life-10-00094]\]. In twenty-three studies, HA \[[@B54-life-10-00094],[@B60-life-10-00094],[@B61-life-10-00094],[@B62-life-10-00094],[@B63-life-10-00094],[@B65-life-10-00094],[@B66-life-10-00094],[@B67-life-10-00094],[@B68-life-10-00094],[@B69-life-10-00094],[@B70-life-10-00094],[@B71-life-10-00094],[@B76-life-10-00094],[@B77-life-10-00094],[@B78-life-10-00094],[@B79-life-10-00094],[@B82-life-10-00094],[@B83-life-10-00094],[@B84-life-10-00094],[@B87-life-10-00094],[@B90-life-10-00094],[@B91-life-10-00094]\] was used as a control, in ten studies placebo was used as a control (saline, no injection, physical therapy) \[[@B54-life-10-00094],[@B56-life-10-00094],[@B57-life-10-00094],[@B73-life-10-00094],[@B79-life-10-00094],[@B80-life-10-00094],[@B85-life-10-00094],[@B86-life-10-00094],[@B88-life-10-00094],[@B91-life-10-00094]\], in four studies corticosteroids \[[@B58-life-10-00094],[@B59-life-10-00094],[@B74-life-10-00094],[@B77-life-10-00094]\] were used as the control, and in two studies acetaminophen \[[@B55-life-10-00094],[@B64-life-10-00094]\] was used as the control.

Thirty-three trials were included in the meta-analysis and another five were excluded due to being non-blinded \[[@B64-life-10-00094],[@B77-life-10-00094],[@B82-life-10-00094],[@B83-life-10-00094],[@B84-life-10-00094]\].

Twenty-three studies reported pain via the VAS comparing PRP versus placebo \[[@B54-life-10-00094],[@B55-life-10-00094],[@B56-life-10-00094],[@B57-life-10-00094],[@B69-life-10-00094],[@B86-life-10-00094]\], corticosteroids \[[@B58-life-10-00094],[@B59-life-10-00094],[@B77-life-10-00094]\] or HA \[[@B54-life-10-00094],[@B60-life-10-00094],[@B61-life-10-00094],[@B62-life-10-00094],[@B63-life-10-00094],[@B65-life-10-00094],[@B66-life-10-00094],[@B67-life-10-00094],[@B68-life-10-00094],[@B69-life-10-00094],[@B70-life-10-00094],[@B71-life-10-00094],[@B76-life-10-00094],[@B77-life-10-00094],[@B78-life-10-00094],[@B79-life-10-00094],[@B87-life-10-00094]\] ([Figure 10](#life-10-00094-f010){ref-type="fig"}). Placebo and HA subgroups showed significant differences in favor of PRP (*p* \< 0.00001), despite the steroid subgroup showing non-significant differences in favor of PRP (*p* = 0.23). The pooled estimates for these studies also showed significant differences in favor of PRP (*p* \< 0.00001). Six studies comparing single versus multiple (two or three times) injections of PRP assessed significant differences in favor of multiple injections (*p* = 0.0008) ([Figure 11](#life-10-00094-f011){ref-type="fig"}). However, only three injections of PRP showed significant differences compared to a single injection (*p* \< 0.00001).

Functional outcome was measured in twenty-eight studies via the WOMAC scale. One study was excluded from meta-analysis due to the reporting of only WOMAC pain scores \[[@B63-life-10-00094]\]. Twenty-five studies compared PRP versus control groups: placebo \[[@B55-life-10-00094],[@B56-life-10-00094],[@B57-life-10-00094],[@B64-life-10-00094],[@B69-life-10-00094],[@B72-life-10-00094],[@B73-life-10-00094],[@B86-life-10-00094],[@B88-life-10-00094],[@B89-life-10-00094],[@B91-life-10-00094]\], corticosteroids \[[@B59-life-10-00094],[@B77-life-10-00094]\] or HA \[[@B62-life-10-00094],[@B63-life-10-00094],[@B65-life-10-00094],[@B67-life-10-00094],[@B68-life-10-00094],[@B69-life-10-00094],[@B71-life-10-00094],[@B75-life-10-00094],[@B77-life-10-00094],[@B79-life-10-00094],[@B82-life-10-00094],[@B83-life-10-00094],[@B84-life-10-00094],[@B87-life-10-00094],[@B89-life-10-00094],[@B90-life-10-00094],[@B91-life-10-00094]\] ([Figure 12](#life-10-00094-f012){ref-type="fig"}). The pooled estimates for these studies showed significant differences in favor of PRP (*p* \< 0.00001); furthermore each subgroup showed significant differences in favor of PRP (*p* \< 0.00001). Functional outcomes were also analyzed in five studies \[[@B59-life-10-00094],[@B80-life-10-00094],[@B85-life-10-00094],[@B86-life-10-00094],[@B87-life-10-00094]\] comparing single versus multiple injections and showed significant differences in favor of multiple injections (*p* \< 0.00001), both in all studies and subgroups ([Figure 13](#life-10-00094-f013){ref-type="fig"}).

Six studies evaluated functional outcomes in IKDC rating scores \[[@B54-life-10-00094],[@B60-life-10-00094],[@B63-life-10-00094],[@B66-life-10-00094],[@B70-life-10-00094],[@B78-life-10-00094],[@B89-life-10-00094]\] and showed significant differences in favor of PRP (*p* = 0.002) ([Figure 14](#life-10-00094-f014){ref-type="fig"}). Five studies showed significant differences in favor of PRP compared to HA as a control group (*p* = 0.004) \[[@B60-life-10-00094],[@B63-life-10-00094],[@B66-life-10-00094],[@B70-life-10-00094],[@B78-life-10-00094]\], and two studies showed non-significant differences in favor of PRP when compared with placebo (*p* = 0.24) \[[@B54-life-10-00094],[@B89-life-10-00094]\].

Eight studies evaluated osteoarthritis outcomes via KOOS scores \[[@B56-life-10-00094],[@B58-life-10-00094],[@B60-life-10-00094],[@B61-life-10-00094],[@B74-life-10-00094],[@B76-life-10-00094],[@B78-life-10-00094],[@B81-life-10-00094]\] ([Figure 15](#life-10-00094-f015){ref-type="fig"}). We excluded from the meta-analysis two of these studies, due to the lack of measurements in one \[[@B56-life-10-00094]\] and division of the results according to the physician in another \[[@B76-life-10-00094]\]. The pooled estimates for these studies showed non-significant differences in KOOS sport (*p* = 0.60), quality of life (*p* = 0.78), and ADL (*p* = 0.69) sub-scales in favor of PRP (*p* \> 0.05), but in KOOS symptoms (*p* = 0.23) and pain (0.97) sub-scales were in favor of the control groups (*p* \> 0.05).

Functional outcomes were also measured with the KSS score in one study \[[@B68-life-10-00094]\], Lysholm score in two studies \[[@B63-life-10-00094],[@B68-life-10-00094]\], Tegner score in four studies \[[@B60-life-10-00094],[@B68-life-10-00094],[@B70-life-10-00094],[@B79-life-10-00094]\], Outcome Measures in Arthritis Clinical Trials--Osteoarthritis Research Society International (OMERACT--OARSI) pain measure in three studies \[[@B56-life-10-00094],[@B75-life-10-00094],[@B90-life-10-00094]\], and Lequesne score in five studies \[[@B59-life-10-00094],[@B68-life-10-00094],[@B71-life-10-00094],[@B75-life-10-00094],[@B90-life-10-00094]\]. Quality of life was measured with SF-36 scores in five studies \[[@B56-life-10-00094],[@B57-life-10-00094],[@B64-life-10-00094],[@B82-life-10-00094]\], SF-12 in two studies \[[@B55-life-10-00094],[@B76-life-10-00094]\], and European Quality of Life (EQoL) in two studies \[[@B61-life-10-00094],[@B76-life-10-00094]\]. Significant improvement was shown in all KSS and Lysholm scores (*p* \< 0.05), in 3/5 studies for the Lequesne score \[[@B59-life-10-00094],[@B68-life-10-00094],[@B75-life-10-00094]\], and 1/3 study for OMERACT--OARSI scores \[[@B75-life-10-00094]\]. No study detected significant difference in Tegner scores.

Twenty-six studies reported adverse events ([Figure 16](#life-10-00094-f016){ref-type="fig"}). Seven studies \[[@B56-life-10-00094],[@B57-life-10-00094],[@B72-life-10-00094],[@B73-life-10-00094],[@B86-life-10-00094],[@B88-life-10-00094],[@B89-life-10-00094]\] comparing PRP versus placebo reported non-significant differences in favor of the control groups (*p* = 0.21), fourteen studies \[[@B60-life-10-00094],[@B61-life-10-00094],[@B65-life-10-00094],[@B67-life-10-00094],[@B68-life-10-00094],[@B69-life-10-00094],[@B70-life-10-00094],[@B71-life-10-00094],[@B75-life-10-00094],[@B76-life-10-00094],[@B77-life-10-00094],[@B79-life-10-00094],[@B83-life-10-00094],[@B84-life-10-00094],[@B87-life-10-00094],[@B90-life-10-00094],[@B91-life-10-00094]\] comparing PRP versus HA reported non-significant differences in favor of the control groups (*p* = 0.27), one study \[[@B58-life-10-00094]\] comparing PRP versus steroids reported no adverse events \[[@B81-life-10-00094]\], and one study comparing PRP versus MSC showed non-significant differences in favor of PRP (*p* = 0.60) \[[@B81-life-10-00094]\]. The pooled estimates for these studies showed non-significant differences in favor of the control groups (*p* = 0.15).

One study was at high risk of bias for three domains \[[@B84-life-10-00094]\], two studies were at high risk of bias for two domains \[[@B83-life-10-00094],[@B85-life-10-00094],[@B87-life-10-00094]\], and twelve studies were at high risk of bias for one domain \[[@B54-life-10-00094],[@B59-life-10-00094],[@B62-life-10-00094],[@B66-life-10-00094],[@B67-life-10-00094],[@B68-life-10-00094],[@B69-life-10-00094],[@B71-life-10-00094],[@B76-life-10-00094],[@B78-life-10-00094],[@B86-life-10-00094],[@B91-life-10-00094]\]. One study was at high risk of performance bias for three domains with the risk of reporting bias for two domains \[[@B82-life-10-00094]\], one study was at high risk of performance bias for two domains with risk of reporting bias for two domains \[[@B77-life-10-00094]\], one study was at high risk of performance bias for two domains with risk of reporting bias for one domain \[[@B64-life-10-00094]\], and two studies were at risk of reporting bias for one domain \[[@B57-life-10-00094],[@B88-life-10-00094]\]. Low risk of performance bias was identified in seventeen studies, moderate risk of performance bias was identified in seventeen studies, and high risk of performance bias was identified in four studies ([Figure 17](#life-10-00094-f017){ref-type="fig"}).

3. Discussion {#sec3-life-10-00094}
=============

In recent years, blood derived products have been gaining more popularity in orthopedic treatment---especially platelet-rich plasma---due to their mechanism of action leading to stem cell proliferation, modulation of inflammatory processes, and angiogenesis \[[@B92-life-10-00094]\]. It has resulted in an increased number of publications regarding the use of PRP in both conservative and intraoperative treatment, including systematic reviews and meta-analysis. However, this meta-analysis is the first concerning PRP applications in all knee diseases.

The most important finding of our study was that PRP has some benefits in almost all analyzed subgroups. PRP improves outcomes in osteoarthritis applications, as well as in arthroscopic treatment of cartilage degeneration. PRP also has an influence on meniscus healing, faster return to sport after muscle injuries, and reduces blood loss after total knee replacement.

Dupley et al. included two RCTs in their meta-analysis comparing PRP injection to ESWT or dry needling. They reported no significant differences in mean VISA-P scores at early follow-up (two or three months; difference in means, 11.9; standard error (SE), 7.4; 95% CI (--2.7, 26.4); *p* = 0.109). However, PRP was statistically better than the control at longer assessment periods (at six months or more than six months; difference in means, 12.7; SE, 4.4; 95% CI (4.1, 21.3); *p* = 0.004) \[[@B93-life-10-00094]\]. Chen et al. included 11 studies in their meta-analysis, but only two RCTs \[[@B7-life-10-00094],[@B8-life-10-00094]\], the same as Dupley et al. \[[@B93-life-10-00094]\], both comparing the application of PRP to control in VISA-P and VAS. The mean difference in functional outcome was 13.22 (95% CI (2.37, 24.07)). In the pain scale, the mean difference comparing PRP with control groups was −1.87 (95% CI (−3.28, −0.46)) and showed that leukocyte-rich PRP (LR-PRP) has better functional improvement and pain reduction for patellar tendinitis compared with corticosteroids, treatment ultrasound, autologous blood injection (ABI) or topical glyceryl trinitrate (TGT) compared to control groups \[[@B94-life-10-00094]\]. In our meta-analysis, four RCTs were included \[[@B6-life-10-00094],[@B7-life-10-00094],[@B8-life-10-00094],[@B9-life-10-00094]\]. The results showed no significant differences in VAS (*p* = 0.78, 95% CI −0.17 (−1.38, 1.04)) and VISA-P scores (*p* = 0.97, 95% CI 0.52 (−11.50,12.54)). Two studies \[[@B8-life-10-00094],[@B9-life-10-00094]\] provided better outcomes in both functional and pain scales. This may be the result of two injections of PRP over two weeks compared with a single injection in other studies \[[@B6-life-10-00094],[@B7-life-10-00094]\]. Further research using a higher number of subjects and with lower biases is needed to state unequivocally that the number of injections positively influences the effect of PRP on PT treatment.

Grassi et al. performed a meta-analysis evaluating outcomes after PRP application in acute muscle injuries \[[@B95-life-10-00094]\]. Six RCTs showed significantly shorter time for return to sport in the PRP group (*p* = 0.006, 95% CI −7.17 (−12.26, −2.08)); however, in three studies with hamstring injuries the difference was not significant (*p* = 0.07, 95% CI −5.95 (−12.48, 0.57)). No other significant differences for fixed-effect meta-analysis among the group were found including re-injury rate, complications, pain, muscle strength, function, ROM, and imaging. Three studies reported better pain outcomes in the PRP group (*p* \< 0.05). Bubnov et al. reported a greater ROM and higher strength in the PRP group \[[@B96-life-10-00094]\]. In our review we analyzed four RCTs which included hamstring injuries. Time for return to sport was significantly shorter in PRP versus control groups (*p* \< 0.00001, 95% CI −4.16 (−5.44, −2.88)). The differences in hamstring meta-analyses may be the result of a narrow range of 95% CI in one additional study (−3.90 (−5.27, −2.53)) or it could be the result of the evaluation of other muscle injures except the hamstring (quadriceps, gastrocnemius) \[[@B10-life-10-00094]\]. We also failed to find any significant differences in re-injury rate (*p* = 0.50). In two studies we also reported lower pain severity. However, more prospective studies for PRP application after muscle injuries are needed as current research shows promising results for a faster return to sport, which can be a major advantage especially for athletes.

In our synthesis we included only two RCTs with PRP application in high tibial osteotomy; this was due to a lack of similar studies. Both RCTs evaluated different outcomes, with significant differences in functional and pain scales, as well as in radiological bone healing and second-look arthroscopy cartilage healing. Roffi et al. performed a systematic review on the application of PRP in bone healing, identifying forty-five pre-clinical in-vivo studies and nineteen clinical studies. Nine clinical studies addressed the role of PRP in the treatment of fractures. Six of them showed improved results in PRP groups regarding radiological parameters. Only five trials reported functional outcomes, with two studies providing improved outcomes. Another ten studies addressed the treatment of delayed or non-unions. Eight of them suggested a positive role for PRP in stimulating bone healing \[[@B97-life-10-00094]\]. The results are promising; however, further research is necessary to confirm the effectiveness of PRP in accelerating bone healing and to exclude bias. Good outcomes in these two studies could be the result of an addition of other myeloid stromal cells.

Muchedzi et al. included seventeen RCTs for evaluation of PRP in both osteoarthritis and following total knee arthroplasty. Primary outcomes after TKA were presented in five studies and included less pain in short-term follow-up in the PRP group (*p* = 0.05, heterogeneity 91%), but no improvements in functional outcome in WOMAC scores. Secondary outcomes were evaluated in ten studies with no significant differences in blood loss (*p* = 0.07). Three studies provided no benefits in length of hospital stay (*p* = 0.31) \[[@B98-life-10-00094]\]. We included six RCTs and analyzed blood loss after TKA to show significant reduction in blood loss in the PRP group (*p* = 0.001, 95% CI −0.29 (−0.46, −0.11)). Four studies reported better outcomes in VAS in the PRP group in short-term follow up. None of the studies showed differences in functional outcomes or range of motion. The differences in outcomes may be a result of study choice as we analyzed only RCTs. Promising results in decreasing pain and blood loss after TKA should encourage further well-planned RCTs with a higher number of patients.

There exists no previous meta-analysis evaluating the use of PRP in addition to arthroscopic surgery. Good outcomes in cartilage healing after PRP injection to knee joint is known \[[@B99-life-10-00094]\]. This suggests that the addition of PRP to surgical treatment might also have a satisfactory effect. Comparing microfractures to PRP injection showed significantly better outcomes in IKDC and Lysholm scores (*p* \< 0.00001; *p* = 0.03) for the PRP group, although the results are only level of evidence III. The positive effects of microfractures in arthroscopic surgery are known, so further extensive research for arthroscopy with concomitant PRP treatment should be encouraged.

Davey et al. analyzed anterior cruciate ligament reconstruction with augmentation of PRP. Thirteen RCTs showed neither significant improvement in any of the clinical outcomes (Tegner, Lysholm, KOOS, IKDC) nor in pain reduction (*p* = 0.18). PRP also does not support graft healing or donor-site morbidity \[[@B100-life-10-00094]\]. In our study including 16 RCTS, we also did not find significant improvements in functional outcomes (IKDC, Lysholm, Tegner), pain reduction (VAS), stability assessment (KT-1000) or tunnel widening. Every outcome crosses the zero line in the forest plot. Currently there is no evidence for supporting ACLR by PRP injection, despite the numerous positive effects of PRP in other diseases.

Haunschild et al. performed a systematic review, including five studies (two prospective and three retrospective) comparing PRP augmentation of meniscus repair to meniscus repair alone. Three studies showed no significant differences in outcome or failure, another two had improvements at the final follow up (KOOS, IKDC, WOMAC, failure). Three studies assessed radiographic findings using MRI: Pujol et al. \[[@B51-life-10-00094]\] showed a significantly improved healing rate (*p* \< 0.01); Kaminski et al. \[[@B47-life-10-00094]\] showed insignificant findings on MRI, although significant improvement was reported in second-look arthroscopy; and Kemmochi et al. \[[@B49-life-10-00094]\] failed to show clearly any improvement only revealing a tendency toward healing. We included in the meta-analysis two additional studies (two RCTs and five non-randomized). Six studies of meniscal repair failure reported significant differences in favor of the PRP group (*p* = 0.003, 95% CI 0.33 (0.18; 0.60)), one study \[[@B49-life-10-00094]\] was excluded because of unclear criteria of improvements in a follow-up MRI and lack of exact outcomes. When comparing with previous analysis where improvements in failure rate were not clearly demonstrated, it is probable that we added two more studies with high weight in our meta-analysis (29.6%, 24.6%). Six studies reported functional outcomes, but only three of them reported significant improvements in some of the scores (KOOS, IKDC, WOMAC). There is insufficient evidence for the addition of PRP to meniscus repair treatment, however, we conclude there are some promising results which should encourage more randomized clinical trials in the near future.

Zhang et al. performed a systematic review of thirteen studies (ten RCTs, three prospective) comparing PRP application in osteoarthritis versus hyaluronic acid. Pain outcomes estimated by VAS did not reveal significant differences and WOMAC pain was significantly decreased after 6 and 12 months of follow-up (*p* \< 0.01; mean difference (MD = −15.25; 95% CI: −22.17 to −8.32). In addition, WOMAC physical function showed significant differences in favor of the PRP group (*p* \< 0.01; MD 11.17; 95% CI (--16.37, --5.98). Functional outcomes in IKDC scale was significant at 6 months of follow-up (*p* \< 0.01), however differences were not significant among the groups after 12 months (*p* = 0.13) \[[@B101-life-10-00094]\]. Similarly, Vilchez-Cavazos et al. evaluated the treatment of knee osteoarthritis comparing a single PRP injection versus multiple PRP injections. Five RCTs measured pain and functional outcomes showing insignificant differences in favor of multiple injections in pain scores (*p* = 0.19; 95% CI 0.65 (−0.31; 1.60)) but significantly better results on joint function in the WOMAC score when comparing multiple injections versus single injection (*p* \< 0.0001; 95% CI 2.24 (1.12, 3.36)) \[[@B102-life-10-00094]\]. Our analysis of PRP injection in the treatment of an osteoarthritic knee included thirty-eight studies. Hyaluronic acid, corticosteroids, saline, no injection, and acetaminophen were evaluated as control groups. The most significant conclusion was that multiple injections were significantly more effective than a single injection with respect to pain (VAS, *p* = 0.0008, 95% CI 1.63 (0.67; 2.59)) and functional outcomes (WOMAC, *p* \< 0.00001, 95% CI 9.46 (6.25; 12.67)). However, we did not find any correlation between injection intervals and clinical outcomes. PRP application was repeated after 1, 2, 3 or 4 weeks. Only one study assessed the effects of a different number of PRP injections. Kavadar et al. compared one, two, and three injections of PRP in grade 3 OA. Mean differences in VAS and TUG (Timed Up and Go Test) significantly favored multiple injections (1 inj. vs. 2 inj., 1 inj. vs. 3 inj., and 2 inj. vs. 3 inj.), but WOMAC mean differences were significant only in comparison of single versus multiple injections \[[@B80-life-10-00094]\]. There is a strong need for more RCTs evaluating the effectiveness of multiple injections of PRP and answering the question: Is twice the applications of PRP injection satisfactory for an optimal clinical effect or does effectiveness improve with the number of injections? Our significant results in pain outcomes derive from the accurate VAS measurements; Vilchez-Cavazos used change in pain data for comparison, despite the fact that even a single injection of PRP significantly improved pain (*p* \< 0.00001) and functional outcomes in WOMAC and IKDC (*p* \< 0.00001; *p* = 0.002) versus control groups. Only in KOOS scores were differences not significant for pooled estimates studies. This might be a result of the small group of included studies. Furthermore, 50% of these studies (3/6) included hyaluronic acid as a control group which was the only one showing insignificant differences in favor of control groups. Some authors concluded that this could be the reason for using LR-PRP or an older population of patients \[[@B60-life-10-00094]\]. The analysis of adverse events also showed the advantage of PRP over other treatments. Differences were not significant but still PRP seems to be the safer option for patients (*p* = 0.15; 95% CI 1.40 (0.88, 2.22)).

There is no single method of PRP preparation and there are many devices and protocols being used. In our synthesis, the most frequently applied centrifuge was the GPS System III (Zimmer Biomet). In addition, there is no evidence for improved outcomes after leukocyte addition to PRP. Most of the studies used leukocyte-rich platelet-rich plasma. There were only two studies in our metanalysis comparing Leukocyte-poor and leukocyte-rich PRP. The first, in the patellar tendinopathy section, showed a non-significant difference in VISA and VAS scores in favor of leucocyte-rich PRP \[[@B6-life-10-00094]\]. A second study which compared PRGF (leukocyte poor) with leukocyte-rich PRP, showed only a significant difference in swelling scores on the first day and CRP ten days after surgery in favor of PRGF. There is a lack of studies comparing leukocyte concentration in PRP to clinical outcomes. Hanish et al. did not find any significant differences between leukocyte-poor (LP)-PRP and LR-PRP in treatment of Achilles tendinopathy in VISA-A and VAS \[[@B103-life-10-00094]\]. Further, Yerlikali et al. showed no significant differences in pain, functional parameters, and inflammatory reaction between LR-PRP and LP-PRP in patients with lateral epicondylitis \[[@B104-life-10-00094]\]. Riboh et al. performed a meta-analysis including six RCTs and three prospective comparative studies comparing efficacy of leukocyte concentration in OA treatment. The final analysis included WOMAC score, IKDC score, and adverse events. They showed a slight advantage in functional outcomes favoring LP-PRP, but leukocyte concentration did not influence upon adverse reactions \[[@B105-life-10-00094]\]. Despite the small amount of studies, leukocytes may be important factors in supporting the action of PRP. They play a role in regeneration through stimulation of immune processes. Lana et al. suggested leukocyte-rich PRP may have some benefits over leukocyte-poor PRP, due to macrophage inclusion, which are "like instructors of the healing orchestra", because of their role in remodeling and repair phases \[[@B106-life-10-00094]\]. On the other hand, Braun et al. concluded that leukocytes provide acute inflammatory response and LP-PRP leads to better outcomes of synovial cell treatment than LR-PRP \[[@B107-life-10-00094]\]. There is a strong need for further research on the effectiveness of LP and LR-PRP.

Our metanalysis showed and summarized many positive effects of PRP. However, there are still many unsolved questions and issues requiring specific studies that should be performed according to the "DOSES" cell-therapy communication tool \[[@B108-life-10-00094]\]. This standardized system for describing cell therapies allows the systematic performance of RCTs and full clinical outcome assessment of PRP in knee disorders.

3.1. Strengths {#sec3dot1-life-10-00094}
--------------

Our major strength is that this synthesis includes comprehensive analysis of PRP application in the treatment of major knee lesions. We performed level of evidence I analysis in all types of lesions but two, which included level of evidence III studies. Our promising results could be a result of a large amount of included RCTs and wide array of control groups. This reduces the risk of bias and provides a more complete and reliable analysis.

3.2. Limitations {#sec3dot2-life-10-00094}
----------------

English language trials were included, but non-English language studies were excluded; they also may contain relevant research. The PRP preparation kits were heterogeneous and not always clearly defined, furthermore platelet count and leukocyte content differed. Level of evidence of included studies varied (I--II). Five of seven included studies in one subgroup were non-randomized (level of evidence III). Some studies with a high risk of bias could have influenced the final results of this synthesis. The diversity of scales used did not allow us to perform meta-analysis of every outcome. Additionally, some of the syntheses consisted of high heterogeneity studies (above 40%).

4. Materials and Methods {#sec4-life-10-00094}
========================

4.1. Search Strategy {#sec4dot1-life-10-00094}
--------------------

In this review we concentrated on PRP application in knee lesions compared with placebo- or other treatment control groups. This study was completed in compatibility with the 2009 Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) statement. A systematic review of the use of platelet-rich plasma in knee lesions was completed with a comprehensive published literature search through PubMed, Embase, Cochrane Database of Systematic Reviews, and Clinicaltrials.gov. The references of the investigations found in this search were cross-referenced to identify additional pertinent studies not identified in the original searches. All searches were performed in February 2020. The searches were performed combining the following keywords: (1) "PRP" or "platelet-rich plasma" or "plasma rich in growth factors" or "platelet derived growth factor" or "platelet derived" or "platelet gel" or "platelet concentrate" or "PRF" or "platelet rich fibrin" or "ACP" or "autologous conditioned plasma" or "PRGF" or "platelet lysate", and (2) "knee" or "knee osteoarthritis" or "meniscus" or "menisci" or "chondral" or "cartilage" or "ligament" or "patella" or "patellar" or "PCL" or "MCL" or "iliotibial" or "osteochondritis" or "hamstring" or "quadriceps" or "epicondyle" or "osteonecrosis" or "arthroscopy" or "tibia" or "tibial" or "femur" or "femoral" or "trochlea" or "posterolateral" or "posteromedial" or "chondrocyte" or "articular" or "arthroplasty" or "osteotomy" or "red zone" or "white zone" or "extrusion" or "red-white" or "intra-meniscal". Systematic review registration was performed on 10.02.2020 using PROSPERO (International Prospective Register of Systematic Reviews, ID 167715).

4.2. Inclusion and Exclusion Criteria {#sec4dot2-life-10-00094}
-------------------------------------

This review included all clinical studies meeting the following inclusion criteria: PRP utilization as conservative treatment in knee lesions or as support in knee surgery, English language, human subjects, paper published in a peer-reviewed journal, and full text available. Only randomized controlled trials were included, in addition to the meniscus and microfractures section where only a small number of RCTs was identified. Exclusion criteria included all animal studies, basic scientific investigations, case reports, review articles, expert opinions, letters to editor, studies without control groups, studies not using PRP, papers not peer reviewed, papers not in English, trials evaluating platelet-poor plasma, and investigations on other diseases unrelated to the knee joint. The investigations included in this study were independently reviewed by two orthopedic surgeons/authors for inclusion and exclusion criteria.

4.3. Types of Interventions {#sec4dot3-life-10-00094}
---------------------------

We compared intralesional, injected PRP preparation with:-placebo injection (low volume saline injection, matching the prp volume);-high volume saline image guided injection;-local steroids injection;-hyaluronic acid injection;-exercise and other physical therapies (e.g., low-dose radiation therapy, eccentric loading program, dry needling);-any other medications given locally or systemically aimed at treating pain; and-combinations of the active interventions listed above.

4.4. Outcomes {#sec4dot4-life-10-00094}
-------------

Primary outcomes included:-pain as measured by standard validated pain scale, such as visual analogue score (VAS), EQ-VAS or numerical rating scale (NRS);-functional measurement by any standard validated scale, such as the International Knee Documentation Committee (IKDC), Western Ontario and McMaster Universities Osteoarthritis Index (WOMAC), Knee Society Score (KSS), Victorian Institute of Sport Assessment (VISA), 36-Item Short Form Survey (SF-36), Knee injury and Osteoarthritis Outcome Score (KOOS), Lysholm Knee Scoring Scale, Teger Activity Score, and Ikeuchi grade knee rating scale;-meniscal repair failure;-time for return to sport;-re-injury;-knee stability, measured as tibial translation;-graft integration; and-tunnel widening.

Adverse events were also evaluated and analyzed. If multiple time points were reported within our time frames, we extracted the last time point (e.g., if data were reported at six weeks, three months, six months, and one year, we extracted outcomes at one year).

4.5. Data Collection and Analysis {#sec4dot5-life-10-00094}
---------------------------------

For each study included in the analysis, the following data were extracted by two independent reviewers: authors, year of publication, type of knee lesions, details of interventions in the study, sample size (randomized and analyzed), outcome measurements, follow-up period, main results, and percentage and type of adverse events included in the publication. Each study's level of evidence was examined and evaluated based on criteria established by Oxford Centre for Evidence-Based Medicine Levels of Evidence Working Group \[[@B109-life-10-00094]\]. Measures of treatment effect at a final point were the mean and standard deviation for continuous outcome measures. When studies reported other measures (e.g., median) and other dispersion measures such as standard error (SE) of the mean or 95% CI of the mean, range or interquartile range (IQR) we calculated the SD in order to perform the relevant meta-analytical pooling according to previous studies (see \[[@B110-life-10-00094],[@B111-life-10-00094]\]).

The study weight was calculated using the Mantel--Haenszel method. We assessed statistical heterogeneity using Tau^2^ or Chi^2^, df and I^2^ statistics. The I^2^ statistic describes the percentage of total variation across trials that is due to heterogeneity. In the case of low heterogeneity (I^2^ \< 40%), studies were pooled using a fixed-effects model, otherwise a random-effects analysis was made.

Subgroup analysis was undertaken for the type of clinical trial and for the type of control intervention.

4.6. Assessment of Risk of Bias {#sec4dot6-life-10-00094}
-------------------------------

Revised Cochrane risk-of-bias tool was used to evaluate risk. Disagreement in the risk of bias assessment was resolved by consensus and, if necessary, by the opinion of a third reviewer. A study was deemed to be:-"low risk" if all items were scored as "low risk"-"moderate risk" if up to two items were classified as "high risk" or "unclear risk"-"high risk" if more than two items were scored as "high risk"

We presented our assessment of risk of bias using two "Risk of Bias" summary figures for every sub-section of the manuscript.

4.7. Statistical Analysis {#sec4dot7-life-10-00094}
-------------------------

Qualitative statistical analysis and meta-analysis were performed using R software and REVMAN 5.3 \[[@B112-life-10-00094],[@B113-life-10-00094]\] with *p*-values of \< 0.05.

5. Conclusions {#sec5-life-10-00094}
==============

Our systematic review and meta-analysis of the clinical use of platelet-rich plasma in knee lesions show some promising results. First of all, our study confirms significant benefits in the use of PRP in osteoarthritis compared with various control groups. PRP is also safe for patients when compared to control groups; there is an insignificant difference in adverse events in favor of control groups. In other subgroups, differences in functional or pain scales or other measured parameters were significant in favor of the PRP group (blood loss in TKA, time to return to sport in hamstring injuries, microfractures augmentation). Some analyzed results showed an advantage of PRP compared to control groups and should lead to further research with a higher number of subjects and with lower biases to state unequivocally that PRP is a necessary component of the treatment (meniscal repair failure). Only one area clearly showed no differences in ACL reconstruction with or without PRP, thus we conclude so far that PRP has not been proved beneficial in ACLR. However, we do recommend PRP application in knee osteoarthritis and suggest performing more clinical trials concerning PRP application in other knee lesions. The optimal protocol (e.g., number of injections, timeframe) for the most effective treatment should be determined. Methods of preparation of platelet-rich plasma need further standardization. Studies should be performed to establish adequate cost--benefit of PRP compared with other standard, less expensive, treatments.
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life-10-00094-t001_Table 1

###### 

Platelet-rich plasma (PRP) compared with control intervention for patellar tendinopathy.

  -----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
                   LOE   Type of Study   Exp                  Cont     Follow-up   Control        Preparation Kit                  LR/LP   Platelet Conc.                             Number of Inj.   PROM       Ref.
  ---------------- ----- --------------- -------------------- -------- ----------- -------------- -------------------------------- ------- ------------------------------------------ ---------------- ---------- -------------------------
  Abate et al.     III   3 arms          PRP 18(18)\          18(18)   6 months    HVIGI saline   Regen Lab A-PRP Kit (Regenlab)   LP      1.6× NPC (Native Platelet Concentration)   2                VISA\      \[[@B9-life-10-00094]\]
                                         HVIGI + PRP 18(18)                                                                                                                                            VAS        

  Dragoo et al.    I     2 arms          10(8)                12(9)    6 months    Dry needling   GPS III (Biomet)                 LR      N/R                                        1                VISA\      \[[@B7-life-10-00094]\]
                                                                                                                                                                                                       Tegner\    
                                                                                                                                                                                                       Lysholm\   
                                                                                                                                                                                                       VAS\       
                                                                                                                                                                                                       SF-12      

  Scott et al.     I     3 arms          LR 19(19)\           19(19)   12 months   Saline         ACs (Arthrex)                    LR/LP   LR 3.8 × 230,000 (51,000)/µL\              1                VISA\      \[[@B6-life-10-00094]\]
                                         LP 19(19)                                                                                         LP 3.0 × 227,000 (43,000)/µL                                NPRS\      
                                                                                                                                                                                                       GROC       

  Vetrano et al.   I     2 arms          23(23)               23(23)   12 months   ESWT           Recover ps kit (Kaylight)        N/R     0.89--1.1 × 10^9^ µL                       2                VISA\      \[[@B8-life-10-00094]\]
                                                                                                                                                                                                       VAS\       
                                                                                                                                                                                                       Blazina    
  -----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

LOE---level of evidence; exp.---no. of patients receiving treatment in experimental group (no. of patients analyzed at final follow-up); cont.---no. of patients receiving treatment in control group (no. of patients analyzed at final follow-up); ESWT---extracorporeal shock wave therapy; HVIGI---high volume image guided injection; LR---leukocyte rich; LP---leukocyte poor; PROM---patient related outcome measures; VAS---visual analog scale; NPRS---Numeric Pain Rating Scale; VISA---Victorian Institute of Sport Assessment; GROC---Global Rating of Change Scales; SF-12---Short Form Survey.

life-10-00094-t002_Table 2

###### 

Platelet-rich plasma (PRP) compared with control intervention for the knee adjacent muscle injuries.

  ---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
                    LOE   Type of Study   Exp.          Cont.    Follow-up   Control        Preparation Kit    LR/LP                   Platelet Concentration   Number of Injections   PROM        Ref.
  ----------------- ----- --------------- ------------- -------- ----------- -------------- ------------------ ----------------------- ------------------------ ---------------------- ----------- --------------------------
  Hamid et al.      II    2 arms          14(12)        14(12)   39 weeks    No injection   GPS III (Biomet)   38.3 × 10^3^/µL         1297 × 10^3^µL           1                      RTS\        \[[@B11-life-10-00094]\]
                                                                                                                                                                                       BPI-SF      

  Hamilton et al.   I     3 arms          PRP 30(26)\   30(29)   6 months    No injection   GPS III (Biomet)   26.1(13.7) × 10^3^/µL   765.8(23.6) × 10^9^/L    1                      RTS\        \[[@B12-life-10-00094]\]
                                          PPP 30(28)                                                                                                                                   Re-injury   

  Reurink et al.    I     2 arms          41(37)        39(36)   1 year      Saline         ACP (Athrex)       1.9(2.1) × 10^3/^µL     433(128) × 10^3^/µL      2                      RTS\        \[[@B13-life-10-00094]\]
                                                                                                                                                                                       Re-injury   

  Rossi et al.      I     2 arms          35(34)        40(38)   2 years     No injection   N/R                N/R                     N/R                      1                      RTS\        \[[@B10-life-10-00094]\]
                                                                                                                                                                                       VAS\        
                                                                                                                                                                                       Re-injury   
  ---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

LOE---level of evidence; exp.---no. of patients receiving treatment in experimental group (no. of patients analyzed at final follow-up); cont.---no. of patients receiving treatment in control group (no. of patients analyzed at final follow-up); LR---leukocyte rich; LP---leukocyte poor; PROM---patient related outcome measures; VAS---visual analog scale; RTS---time for return to sports; BPI-SF---Brief Pain Inventory-Short Form.

life-10-00094-t003_Table 3

###### 

Platelet-rich plasma (PRP) compared with control intervention for high tibial osteotomy.

  ---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
                   LOE   Type of Study   Exp.             Cont.              Follow-up   Control             Preparation Kit   LR/LP   Platelet Concentration       Number of Injections   PROM                Ref.
  ---------------- ----- --------------- ---------------- ------------------ ----------- ------------------- ----------------- ------- ---------------------------- ---------------------- ------------------- --------------------------
  Dallari et al.   I     3 arms          PG 1(9)\         10(9)              1 year      Lyophilized bone\   N/R               N/R     1 × 10^6^/µL                 1                      KSS\                \[[@B15-life-10-00094]\]
                                         PG + BM 12(10)                                  chips                                                                                             ROM\                
                                                                                                                                                                                           Osteointegration\   
                                                                                                                                                                                           histomorphometric   

  Koh et al.       II    2 arms          26(23)           PRP + MSC 26(21)   2 years     PRP + MSC           N/R               N/R     1303.27 (375.2) × 10^3^/µL   1                      Lysholm\            \[[@B14-life-10-00094]\]
                                                                                                                                                                                           VAS\                
                                                                                                                                                                                           KOOS                
  ---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

LOE---level of evidence; exp.---no. of patients receiving treatment in experimental group (no. of patients analyzed at final follow-up); cont.---no. of patients receiving treatment in control group (no. of patients analyzed at final follow-up); LR---leukocyte rich; LP---leukocyte poor; ROM---range of movement; PROM---patient related outcome measures; VAS---visual analog scale; KSS---Knee Society Score; Lysholm---Lysholm Knee Scoring Scale.

life-10-00094-t004_Table 4

###### 

Platelet-rich plasma (PRP) compared with control intervention for TKA.

  ---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
                            LOE   Type of Study   Exp.                         Cont.    Follow-up   Control        Preparation Kit   LR/LP   Platelet Concentration   Number of Injections   PROMs       Ref.
  ------------------------- ----- --------------- ---------------------------- -------- ----------- -------------- ----------------- ------- ------------------------ ---------------------- ----------- --------------------------
  Guerreiro\                I     2 arms          20(20)                       20(20)   2 months    no injection   Fanem             LP      988,250                  1                      VAS\        \[[@B19-life-10-00094]\]
  et al. (2015)                                                                                                                                                                              WOMAC\      
                                                                                                                                                                                             HgB drop\   
                                                                                                                                                                                             ROM\        
                                                                                                                                                                                             Ht\         
                                                                                                                                                                                             Wound       

  Guerreiro et al. (2019)   I     4 arms          PRP 20(16)\                  21(21)   2 years     saline         Fanem             LP      618,500                  1                      VAS\        \[[@B20-life-10-00094]\]
                                                  PRP + TXA 20(18)TXA 23(13)                                                                                                                 WOMAC\      
                                                                                                                                                                                             HgB drop\   
                                                                                                                                                                                             ROM\        
                                                                                                                                                                                             Wound       

  Horstman et al.           I     2 arms          20(20)                       20(20)   10 days     no injection   GPS (Biomet)      LR      N/R                      1                      VAS\        \[[@B16-life-10-00094]\]
                                                                                                                                                                                             HgB drop\   
                                                                                                                                                                                             ROM\        
                                                                                                                                                                                             wound       

  Mochizuk et al.           I     2 arms          109                          206      14 days     no injection   N/R               N/R     N/R                      1                      HgB drop\   \[[@B21-life-10-00094]\]
                                                                                                                                                                                             ROM\        
                                                                                                                                                                                             BL          

  Morishita et al.          I     2 arms          20(20)                       20(20)   28 days     no injection   ACS (Exactech)    LR      23.4 × 104/µL            1                      KOOS\       \[[@B17-life-10-00094]\]
                                                                                                                                                                                             KSS\        
                                                                                                                                                                                             HgB drop\   
                                                                                                                                                                                             ROM\        
                                                                                                                                                                                             BL\         
                                                                                                                                                                                             CRP         

  Peerboom et al.           II    2 arms          50(32)                       52(41)   3 months    no injection   GPS (Biomet)      N/R     N/R                      1                      VAS\        \[[@B18-life-10-00094]\]
                                                                                                                                                                                             WOMAC\      
                                                                                                                                                                                             HgB drop\   
                                                                                                                                                                                             ROM\        
                                                                                                                                                                                             wound       
  ---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

LOE---level of evidence; exp.---no. of patients receiving treatment in experimental group (no. of patients analyzed at final follow-up); cont.---no. of patients receiving treatment in control group (no. of patients analyzed at final follow-up); LR---leukocyte rich; LP---leukocyte poor; ROM---range of movement; BL---blood loss; wound---wound healing; CRP---C reactive protein; HgB---hemoglobin; Ht---hematocrit; PROM---patient related outcome measures; VAS---visual analog scale; WOMAC---Western Ontario and McMaster Universities Osteoarthritis Index; KSS---Knee Society Score; KOOS---Knee injury and Osteoarthritis Outcome Score.

life-10-00094-t005_Table 5

###### 

Platelet-rich plasma (PRP) compared with control intervention as adjunct treatment for arthroscopy.

  ----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
                       LOE   Type of Study   Exp                Cont              Follow-up   Control             Preparation Kit               LR/LP   Platelet Concentration   Number of Inj.   PROM          Ref.
  -------------------- ----- --------------- ------------------ ----------------- ----------- ------------------- ----------------------------- ------- ------------------------ ---------------- ------------- --------------------------
  Duif et al.          II    2 arms          24(21)             34(32)            12 months   no injection        ACP (Arthrex)                 LP      N/R                      1                VAS\          \[[@B23-life-10-00094]\]
                                                                                                                                                                                                  IKDC\         
                                                                                                                                                                                                  Lysholm\      
                                                                                                                                                                                                  SF-36         

  Kim et al. (2015)    III   2 arms          MCS + PRP 71(20)   94(20)            24 months   MSC + fibrin glue   Process Protocol              N/R     1.28 × 10^6^/µL          1                IKDC\         \[[@B28-life-10-00094]\]
                                                                                                                                                                                                  Tegner\       
                                                                                                                                                                                                  ICRS          

  Lee et al.           I     2 arms          24(24)             25(25)            24 months   microfracture       Magellan APS (MBTD)           N/R     N/R                      1                VAS\          \[[@B24-life-10-00094]\]
                                                                                                                                                                                                  IKDC\         
                                                                                                                                                                                                  Lysholm       

  Manunta et al.       II    2 arms          10                 10                12 months   microfracture       GPS II (Biomet)               N/R     N/R                      3                VAS\          \[[@B25-life-10-00094]\]
                                                                                                                                                                                                  IKDC          

  Manco et al.         III   2 arms          14                 13                24 months   microfracture       Manual                        N/R     0.3--1.5 × 10^6^         1                VAS\          \[[@B27-life-10-00094]\]
                                                                                                                                                                                                  IKDC\         
                                                                                                                                                                                                  SF-36         

  Nguyen et al.        III   2 arms          15(15)             15(15)            18 months   microfracture       New-PRP Pro Kit (GeneWorld)   N/R     N/R                      1                WOMAC\        \[[@B26-life-10-00094]\]
                                                                                                                                                                                                  VAS\          
                                                                                                                                                                                                  Lysholm\      
                                                                                                                                                                                                  Outerbridge   

  Vasavilbaso et al.   I     5 arms          10(10)             control 10(10)\   18 months   no injection\       GPS II (Biomet)               N/R     N/R                      1                WOMAC         \[[@B22-life-10-00094]\]
                                                                HA 3 10(10)\                  HA                                                                                                                
                                                                HA 4 10(10)\                                                                                                                                    
                                                                HA 5 10(10)                                                                                                                                     
  ----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

LOE---level of evidence; exp.---no. of patients receiving treatment in experimental group (no. of patients analyzed at final follow-up); cont.---no. of patients receiving treatment in control group (no. of patients analyzed at final follow-up); LR---leukocyte rich; LP---leukocyte poor; ROM---range of movement; BL---blood loss; wound---wound healing; CRP---C reactive protein; HgB---hemoglobin; Ht---hematocrit; PROM---patient related outcome measures; VAS---visual analog scale; WOMAC---Western Ontario and McMaster Universities Osteoarthritis Index; SF-36---36-Item Short Form Survey; Outerbridge---Outerbrige cartilage injury scale; Lysholm---Lysholm Knee Scoring Scale; IKDC---International Knee Documentation Committee.

life-10-00094-t006_Table 6

###### 

Platelet-rich plasma (PRP) compared with control intervention as adjunct treatment for ACL reconstruction.

  ---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
                         LOE   Type of Study   Exp              Cont      Follow-up   Control                        Preparation Kit                       LR/LP                    Platelet Concentration                Number of Injections   PROM                            Ref.
  ---------------------- ----- --------------- ---------------- --------- ----------- ------------------------------ ------------------------------------- ------------------------ ------------------------------------- ---------------------- ------------------------------- --------------------------
  Almeida et al.         I     2 arms          12(10)           15(12)    6 months    no injection                   995-E (Haemonetics Corp, Braintree)   0.91/mm^3^± 0.81/mm^3^   1,185,166/mm^3^± 404,472/mm^3^        1                      Kujala\                         \[[@B32-life-10-00094]\]
                                                                                                                                                                                                                                                 VAS\                            
                                                                                                                                                                                                                                                 IKDC\                           
                                                                                                                                                                                                                                                 Lysholm\                        
                                                                                                                                                                                                                                                 Tegner                          

  Azcarate et al.        II    3 arms          50(50) PG\       50(50)    12 months   no injection                   Beckman J-6B\                         LP/LR                    837 × 10^6^/mL\                       1                      CRP\                            \[[@B34-life-10-00094]\]
                                               50(50) Endoret                                                        BTI System II                                                  504 × 10^6^/mL                                               VAS\                            
                                                                                                                                                                                                                                                 KT-1000\                        
                                                                                                                                                                                                                                                 IKDC\                           
                                                                                                                                                                                                                                                 MRI                             

  Cervellin et al.       I     2 arms          20(20)           20(20)    12 months   small blood sample             GPS II (Biomet)                       LR                       N/R                                   1                      VAS\                            \[[@B29-life-10-00094]\]
                                                                                                                                                                                                                                                 VISA                            

  Mirzatolooei et al.    I     2 arms          25(23)           25(23)    3 months    no injection                   ACP (Arthrex)                         LP                       N/R                                   1                      CT tunnel widening\             \[[@B41-life-10-00094]\]
                                                                                                                                                                                                                                                 VAS\                            
                                                                                                                                                                                                                                                 ROM\                            
                                                                                                                                                                                                                                                 KT-1000                         

  Orrego et al.          II    4 arms          PC 29(26)\       29 (27)   6 months    no injection                   GPS II (Biomet)                       LR                       N/R                                   1                      MRI\                            \[[@B39-life-10-00094]\]
                                               BP 29(28)\                                                                                                                                                                                        graft maturation\               
                                               PC + BP 29(27)                                                                                                                                                                                    IKDC\                           
                                                                                                                                                                                                                                                 Lysholm                         

  Radice et al.          III   2 arms          25               25        1 year      no injection                   GPS (Biomet)                          N/R                      N/R                                   1                      graft integration MR            \[[@B33-life-10-00094]\]

  Rupreht et al.         II    2 arms          25(21)           25(20)    6 months    no injection                   N/R                                   N/R                      978 × 10^3^/ mm^3^                    1                      tunnel healing\                 \[[@B37-life-10-00094]\]
                                                                                                                                                                                                                                                 MRI                             

  Sanchez et al.         III   2 arms          22(21)           15 (15)   24 months   no injection                   BTI System II                         LP                       2--3 × NPC                            1                      Histology---remodeling graft\   \[[@B40-life-10-00094]\]
                                                                                                                                                                                                                                                 2nd arthroscopy                 

  Seijas et al. (2013)   I     2 arms          49(48)           49(48)    12 months   no injection                   BTI System                            N/R                      N/R                                   1                      MRI\                            \[[@B35-life-10-00094]\]
                                                                                                                                                                                                                                                 graft remodeling                

  Seijas et al. (2016)   I     2 arms          23               20        2 years     no injection                   N/R                                   N/R                      N/R                                   1                      VAS                             \[[@B31-life-10-00094]\]

  Silva et al.           I     4 arms          10 1xprp\        10        3 months    no injection                   GPS III (Biomet)                      LR                       N/R                                   3                      graft integration MR            \[[@B36-life-10-00094]\]
                                               10 3xprp\                                                                                                                                                                                                                         
                                               10 Clotalys                                                                                                                                                                                                                       

  Starantzis et al.      II    2 arms          30(25)           30(26)    1 year      placebo sample                 GPS III (Biomet)                      LR                       N/R                                   1                      MRI\                            \[[@B42-life-10-00094]\]
                                                                                                                                                                                                                                                 CT\                             
                                                                                                                                                                                                                                                 tunnel diameter\                
                                                                                                                                                                                                                                                 Lysholm\                        
                                                                                                                                                                                                                                                 KT-1000                         

  Sözkesen et al.        III   2 arms          18               26        12 months   no injection                   Prosys PRS bio kit (Prodizen)         N/R                      N/R                                   1                      IKDC\                           \[[@B43-life-10-00094]\]
                                                                                                                                                                                                                                                 Lysholm\                        
                                                                                                                                                                                                                                                 Tegner\                         
                                                                                                                                                                                                                                                 KT-1000\                        
                                                                                                                                                                                                                                                 CT tunnel healing               

  Vadala et al.          II    2 arms          20               20        10 months   no injection                   PRP Fast Biotech kit (MyCells)        N/R                      N/R                                   1                      Tegner\                         \[[@B44-life-10-00094]\]
                                                                                                                                                                                                                                                 Lysholm\                        
                                                                                                                                                                                                                                                 IKDC\                           
                                                                                                                                                                                                                                                 KT-1000\                        
                                                                                                                                                                                                                                                 CT tunnel enlargement           

  Ventura et al.         I     2 arms          10(10)           10(10)    6 months    No injection                   GPS (Biomet)                          N/R                      N/R                                   1                      KOOS\                           \[[@B38-life-10-00094]\]
                                                                                                                                                                                                                                                 IKDC\                           
                                                                                                                                                                                                                                                 KT-1000\                        
                                                                                                                                                                                                                                                 Tegner                          

  Walters et al.         II    2 arms          27(17)           23(12)    24 months   bone chips with no injection   ACP (Arthrex)                         LP                       2--3 × NPC (\<750,000 platelets/µL)   1                      VAS\                            \[[@B30-life-10-00094]\]
                                                                                                                                                                                                                                                 VAS ADL\                        
                                                                                                                                                                                                                                                 IKDC                            
  ---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

LOE---level of evidence; exp.---no. of patients receiving treatment in experimental group (no. of patients analyzed at final follow-up); cont.---no. of patients receiving treatment in control group (no. of patients analyzed at final follow-up); LR---leukocyte rich; LP---leukocyte poor; ROM---range of movement; CRP---C reactive protein; MRI---magnetic resonance imaging; CT---computer tomography; PROM---patient related outcome measures; VAS---visual analog scale; WOMAC---Western Ontario and McMaster Universities Osteoarthritis Index; Tegner---Tegner Activity Score; Lysholm---Lysholm Knee Scoring Scale; IKDC---International Knee Documentation Committee.

life-10-00094-t007_Table 7

###### 

Platelet-rich plasma (PRP) compared with control intervention as adjunct treatment for meniscus repair.

  ------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
                          LOE   Type of Study   Exp         Cont       Follow-up   Control        Preparation Kit                       LR/LP                  Platelet Concentration       Number of Inj.   PROM       Ref.
  ----------------------- ----- --------------- ----------- ---------- ----------- -------------- ------------------------------------- ---------------------- ---------------------------- ---------------- ---------- --------------------------
  Dai et al.              III   2 arms          14(13)      15(13)     1 year      no injection   N/R                                   LR                     6.4 ± 1.6 ×NPC               1                Lysholm\   \[[@B53-life-10-00094]\]
                                                                                                                                                                                                             Ikeushi\   
                                                                                                                                                                                                             VAS\       
                                                                                                                                                                                                             Failure    

  Everhart et al.         III   3 arms          203(164)\   347(294)   3 years     no injection   GPS III (Biomet)/\                    LR                     1343 ± 670 k/µL\             1                Failure    \[[@B52-life-10-00094]\]
                                                148\                                              Angel (Arthrex)                                              2064 ± 526 k/µL                                          
                                                55                                                                                                                                                                      

  Griffin et al.          III   2 arms          15(11)      20(15)     2 years     no injection   Cascade Platelet Rich Fibrin Matrix   N/R                    N/R                          1                IKDC\      \[[@B50-life-10-00094]\]
                                                                                                                                                                                                             Tegner\    
                                                                                                                                                                                                             Lysholm\   
                                                                                                                                                                                                             ROM\       
                                                                                                                                                                                                             Failure    

  Kemmochi et al.         II    2 arms          17          5          6 months    no injection   N/R                                   LR\                    5.5 × NPC (3.4--9.1)         1                Tegner\    \[[@B49-life-10-00094]\]
                                                                                                                                        3.6 × NPC (2.0--7.3)                                                 Lysholm\   
                                                                                                                                                                                                             IKDC       

  Kamiński et al., 2018   I     2 arms          19(18)      18(17)     45 months   saline         N/R                                   LR                     N/R                          1                VAS\       \[[@B47-life-10-00094]\]
                                                                                                                                                                                                             KOOS\      
                                                                                                                                                                                                             WOMAC\     
                                                                                                                                                                                                             IKDC\      
                                                                                                                                                                                                             Failure    

  Kamiński et al., 2019   I     2 arms          42(40)      30(29)     54 months   trephination   N/R                                   LR                     823 (320--1659) × 10^3^/µL   1                VAS\       \[[@B48-life-10-00094]\]
                                                                                                                                                                                                             KOOS\      
                                                                                                                                                                                                             IKDC\      
                                                                                                                                                                                                             WOMAC\     
                                                                                                                                                                                                             Failure    

  Pujol et al.            III   2 arms          17(16)      17(15)     2 years     no injection   GPS III (Biomet)                      N/R                    N/R                          1                KOOS\      \[[@B51-life-10-00094]\]
                                                                                                                                                                                                             IKDC\      
                                                                                                                                                                                                             ROM\       
                                                                                                                                                                                                             Failure    
  ------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

LOE---level of evidence; exp.---no. of patients received treatment in experimental group (no. of patients analyzed at final follow-up); cont.---no. of patients receiving treatment in control group (no. of patients analyzed at final follow-up); LR---leukocyte rich; LP---leukocyte poor; ROM---range of movement; PROM---patient related outcome measures; VAS---visual analog scale; WOMAC---Western Ontario and McMaster Universities Osteoarthritis Index; Tegner---Teger Activity Score; Lysholm---Lysholm Knee Scoring Scale; KOOS---Knee injury and Osteoarthritis Outcome Score; Ikeushi---The knee rating scale of Ikeuchi; IKDC---International Knee Documentation Committee.

life-10-00094-t008_Table 8

###### 

Platelet-rich plasma (PRP) compared with control intervention as adjunct treatment for osteoarthritis (blinded RCTs).

  -----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
                                   LOE   Type of Study   Exp.                        Cont.           Follow-up   Control          Preparation Kit                  LR/LP                     Platelet Concentration                     Number of inj.   PROM                      K-L         Ref.
  -------------------------------- ----- --------------- --------------------------- --------------- ----------- ---------------- -------------------------------- ------------------------- ------------------------------------------ ---------------- ------------------------- ----------- --------------------------
  Ahmad et al.                     I     2 arms          PRP 45(45)                  45(44)          6 months    HA               N/R                              LR                        N/R                                        3                VAS\                      1--3        \[[@B66-life-10-00094]\]
                                                                                                                                                                                                                                                         IKDC\                                 
                                                                                                                                                                                                                                                         USG                                   

  Bastos et al. (2018)             II    2 arms          PRP+MSC\                    MSC 9(9)        12 months   MSC              N/R                              N/R                       10^6^/μL                                   1                KOOS\                     1--4        \[[@B81-life-10-00094]\]
                                                         9(9)                                                                                                                                                                                            ROM\                                  
                                                                                                                                                                                                                                                         CFU-F                                 

  Bastos et al. (2019)             II    3 arms          MSCs 16(15)\                17(16)          12 months   CS               FalconTM                         LP                        10^6^/µL                                   1                KOOS\                     1--4        \[[@B74-life-10-00094]\]
                                                         MSCs + PRP 14(14)                                                                                                                                                                               ROM                                   

  Buendia-Lopez et al.             II    3 arms          PRP 35(33)                  HA 36(32)\      52 weeks    HA\              N/R                              LP                        1,095,000 ± 23,200/mm^3^                   1                WOMAC\                    1--2        \[[@B69-life-10-00094]\]
                                                                                     NSAIDs 35(33)               NSAIDs                                                                                                                                  VAS\                                  
                                                                                                                                                                                                                                                         X-ray\                                
                                                                                                                                                                                                                                                         MRI                                   

  Cole et al.                      I     2 arms          PRP 52(49)                  59(50)          52 weeks    HA               ACP                              LP                        1.73 ± 0.053 xNPC                          3                WOMAC\                    1--3        \[[@B63-life-10-00094]\]
                                                                                                                                                                                                                                                         IKDC\                                 
                                                                                                                                                                                                                                                         VAS\                                  
                                                                                                                                                                                                                                                         Lysholm                               

  Duymus et al.                    I     3 arms          PRP 39(33)                  HA 39(34)\      12 months   HA\              Ycellbio kit                     LP                        \>1,500,000/µL                             2                WOMAc\                    2--3        \[[@B62-life-10-00094]\]
                                                                                     Ozone 39(35)                Ozone                                                                                                                                   VAS                                   

  Elik et al.                      I     2 arms          PRP 30(30)                  30(27)          6 months    saline           Revmed, VERSUS-5000 i2           LR                        N/R                                        3                VAS\                      1--3        \[[@B57-life-10-00094]\]
                                                                                                                                                                                                                                                         WOMAC\                                
                                                                                                                                                                                                                                                         SF-36\                                
                                                                                                                                                                                                                                                         USG                                   

  Filardo et al. (2012)            II    2 arms          PRP 54                      55              12 months   HA               N/R                              LR                        5 × NPC                                    3                IKDC\                     1--3        \[[@B78-life-10-00094]\]
                                                                                                                                                                                                                                                         EQ-VAS\                               
                                                                                                                                                                                                                                                         Tegner\                               
                                                                                                                                                                                                                                                         KOOS\                                 
                                                                                                                                                                                                                                                         ROM                                   

  Filardo et al. (2015)            I     2 arms          PRP 96(94)                  93(89)          12 months   HA               N/R                              LR\                       4.6 ± 1.4 x NPC                            3                IKDC\                     0--3        \[[@B60-life-10-00094]\]
                                                                                                                                                                   1.1 ± 0.5 × NLC                                                                       KOOS\                                 
                                                                                                                                                                                                                                                         EQ-VAS\                               
                                                                                                                                                                                                                                                         Tegner\                               
                                                                                                                                                                                                                                                         ROM                                   

  Görmeli et al.                   I     4 arms          PRP 3 44(39)\               HA 44(39)\      6 months    HA\              N/R                              N/R                       5.2 × (1,118,000 µL)\                      3\               EQ-VAS\                   1--3 or 4   \[[@B54-life-10-00094]\]
                                                         PRP 1 45(44)                Saline 43(40)               saline                                                                      5.3 × (1,152,000 µL)                       1                IKDC                                  

  Jubert et al.                    II    2 arms          PRP 35(34)                  30(30)          6 months    CS               N/R                              LP                        0.99 × 10^6^/µL (0.34--1.54 × 10^6^/ µL)   1                VAS\                      3--4        \[[@B58-life-10-00094]\]
                                                                                                                                                                                                                                                         KOOS\                                 
                                                                                                                                                                                                                                                         SF-36                                 

  Kavadar et al.                   I     3 arms          PRP1 34(33)\                \--             6 months    \-               N/R                              LR                        4--5 × NPC                                 1\               VAS\                      3           \[[@B80-life-10-00094]\]
                                                         PRP2 34(32)\                                                                                                                                                                   2\               WOMAC\                                
                                                         PRP3 34(33)                                                                                                                                                                    3                TUG                                   

  Kon et al.                       II    2 arms          APS 31(29)                  15(15)          12 months   saline           nSTRIDE APS Kit (Biomet)         LR                        N/R                                        1                VAS\                      2 or 3      \[[@B56-life-10-00094]\]
                                                                                                                                                                                                                                                         WOMAC\                                
                                                                                                                                                                                                                                                         KOOS\                                 
                                                                                                                                                                                                                                                         SF-36\                                
                                                                                                                                                                                                                                                         CGI-S/C\                              
                                                                                                                                                                                                                                                         PGI-S/C\                              
                                                                                                                                                                                                                                                         OMERACT\                              
                                                                                                                                                                                                                                                         --OARSI\                              
                                                                                                                                                                                                                                                         MRI\                                  
                                                                                                                                                                                                                                                         RTG\                                  
                                                                                                                                                                                                                                                         MRI                                   

  Lana et al.                      I     3 arms          PRP 36(36)HA + PRP 33(33)   36(36)          12 months   HA               N/R                              LR                        800,000--1,600,000/mm^3^                   3                WOMAC,\                   1--3        \[[@B79-life-10-00094]\]
                                                                                                                                                                                                                                                         VAS                                   

  Lin et al.                       I     3 arm           PRP 31(31)                  HA 29(29)\      12 months   HA\              RegenKit-THT                     LP                        1.81 ± 0.34 × NPC                          3                WOMAC\                    Ahlbäck\    \[[@B89-life-10-00094]\]
                                                                                     S 27(27)                    Saline                                                                                                                                  IKDC                      1--3        

  Lisi et al.                      I     2 arm           PRP 28(25)                  22(22)          12 months   HA               N/R                              N/R                       N/R                                        3                WOMAC\                    2--3        \[[@B68-life-10-00094]\]
                                                                                                                                                                                                                                                         Lysholm\                              
                                                                                                                                                                                                                                                         Tegner\                               
                                                                                                                                                                                                                                                         AKSS\                                 
                                                                                                                                                                                                                                                         Lequesne\                             
                                                                                                                                                                                                                                                         VAS\                                  
                                                                                                                                                                                                                                                         ROM                                   

  Louis et al.                     II    2 arms          PRP 26(17)                  28(17)          6 months    Durolane, HA     MultifugeHeraus R                LP                        800 ± 276 × 10^9^/L                        1                WOMAC\                    2--4        \[[@B65-life-10-00094]\]
                                                                                                                                                                                                                                                         VAS\                                  
                                                                                                                                                                                                                                                         RTG\                                  
                                                                                                                                                                                                                                                         ROM                                   

  Di Martino et al.                I     2 arms          PRP 96(85)                  93(82)          24 months   HA               N/R                              1.1 ± 0.5 × NLC           4.6 ±1.4 × NPC                             3                IKDC\                     1--3        \[[@B70-life-10-00094]\]
                                                                                                                                                                                                                                                         EQVAS\                                
                                                                                                                                                                                                                                                         Tegner                                

  Montañez-Heredia et al.          I     2 arms          PRP 28(27)                  27(26)          6 months    HA               N/R                              LP                        952 × 10^9^/L                              1                VAS\                      1--3        \[[@B76-life-10-00094]\]
                                                                                                                                                                                                                                                         KOOS EQoL                             

  Patel et al.                     I     3 arms          PRP1 27(26)\                23(23)          6 months    saline           N/R                              LP                        310.14 × 10^3^/µL                          1\               WOMAC\                    Ahlbäck\    \[[@B86-life-10-00094]\]
                                                         PRP2\                                                                                                                                                                          2                VAS                       1--2        
                                                         25(25)                                                                                                                                                                                                                                

  Paterson et al.                  I     2 arms          PRP 11(10)                  10(9)           12 weeks    HA               Premiere\                        LR                        N/R                                        3                VAS\                      2--3        \[[@B61-life-10-00094]\]
                                                                                                                                  XC-2000                                                                                                                KOOS\                                 
                                                                                                                                                                                                                                                         KQoL\                                 
                                                                                                                                                                                                                                                         Functional tests                      

  Raeissadat et al. (2017)         II    2 arms          PRGF-Endoret 41(36)         36(33)          6 months    HA               Rooyagen\                        LR                        4.6 ± 0.7 × NPC                            2                WOMAC\                    2--3        \[[@B71-life-10-00094]\]
                                                                                                                                  Kit                                                                                                                    Lequesne\                             
                                                                                                                                                                                                                                                         VAS                                   

  Rahimzadeh et al.                I     2 arms          PRP 21(21)                  21(21)          6 months    PRL (dextrose)   Standard kit, Iran               N/R                       N/R                                        2                WOMAC                     1--2        \[[@B73-life-10-00094]\]

  Sánchez et al.                   I     2 arms          PRGF-Endoret 89(79)         87(74)          6 months    HA               BTI Biotechnology\               LP                        N/R                                        3                WOMAC\                    Ahlbäck\    \[[@B90-life-10-00094]\]
                                                                                                                                  Institute system                                                                                                       Lequesne OMERACT--OARSI   1--3        

  Simental- Mendía et al. (2016)   I     2 arms          PRP 33(33)                  32(32)          24 weeks    acetaminophen    N/R                              LP                        513.25 ± 189.3 K/µL                        3                VAS\                      1 or 2      \[[@B55-life-10-00094]\]
                                                                                                                                                                                                                                                         WOMAC, SF-12                          

  Simental-Mendía (2019)           I     2 arms          1 prp 18\                   \-              48 weeks    \-               NR                               LP                        99.3 ± 162.0 × 10^6^/μL                    1\               VAS\                      1--2        \[[@B85-life-10-00094]\]
                                                         3 prp 17                                                                                                                                                                       3                WOMAC\                                
                                                                                                                                                                                                                                                         SF-12                                 

  Smith et al.                     I     2 arms          ACP 15(15)                  15(15)          1 year      saline           Hettich ROTOFIX 32 A; Arthrex    LP                        N/R                                        3                WOMAC                     2--3        \[[@B72-life-10-00094]\]

  Su et al.                        I     3 arms          io 28(27)\                  32(30)          18 months   HA               N/R                              LR\                       789.68 ± 17.80 × 10^9^/L                   2                VAS\                      2--3        \[[@B67-life-10-00094]\]
                                                         ia 26(25)                                                                                                 29.92 ± 1.54 × 10^9^/L.                                                               WOMAC                                 

  Tavassoli et al.                 II    3 arms          PRP 1\                      31(27)          12 weeks    HA               Rooyagen kit                     LR                        N/R                                        1\               WOMAC\                    Ahlbäck\    \[[@B87-life-10-00094]\]
                                                         31(28)\                                                                                                                                                                        2                VAS                       1--4        
                                                         PRP 2\                                                                                                                                                                                                                                
                                                         33(28)                                                                                                                                                                                                                                

  Uslu-Guvendi et al.              II    3 arms          PRP 1\                      19(17)          6 months    CS               N/R                              8.67 10^9^/L              875 10^9^/L                                1\               VNS\                      3           \[[@B59-life-10-00094]\]
                                                         19(19)\                                                                                                                                                                        3                WOMAC\                                
                                                         PRP3\                                                                                                                                                                                           Lequesne                              
                                                         19(14)                                                                                                                                                                                                                                

  Vaquerizo et al.                 I     2 arms          48(48)\                     48(42)          48 weeks    Durolane HA      BTI\                             LP                        N/R                                        3                WOMAC\                    2--4        \[[@B75-life-10-00094]\]
                                                         PRGF-Endoret                                                             Biotechnology Institute system                                                                                         Lequesne\                             
                                                                                                                                                                                                                                                         OMERACT--OARSI                        

  Wu et al.                        I     2 arms          20(20)                      20(20)          6 months    saline           RegenKit-THT-1, Regen Lab        LR                        N/R                                        1                WOMAC\                    Ahlbäck\    \[[@B88-life-10-00094]\]
                                                                                                                                                                                                                                                         Isokineticfunction        1--2        

  Yu et al.                        II    4 arms          PRP 104\                    HA 88\          1 year      HA\              N/R                              N/R                       N/R                                        1                WOMAC\                    \-          \[[@B91-life-10-00094]\]
                                                         PRP + HA 96                 saline 72                   saline                                                                                                                                  Kanofsky                              
  -----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

LOE---level of evidence; exp.---no. of patients receiving treatment in experimental group (no. of patients analyzed at final follow-up); cont.---no. of patients receiving treatment in control group (no. of patients analyzed at final follow-up); LR---leukocyte rich; LP---leukocyte poor; ROM---range of movement; PROM---patient related outcome measures; MRI---magnetic resonance imaging; VAS---visual analog scale; WOMAC---Western Ontario and McMaster Universities Osteoarthritis Index; TUG---tug lesion; Tegner---Teger Activity Score; SF-36---36-Item Short Form Survey; SF-12---12-Item Short Form Survey; PGI-S/C---Patient Global Impression of Severity Scale; OMERACT--OARSI---OMERACT--OARSI osteoarthritis pain measure; Lysholm---Lysholm Knee Scoring Scale; Lequesne---Lequesne index of severity for osteoarthritis; KQol---knee-related quality of life; KOOS---Knee injury and Osteoarthritis Outcome Score; K-L---Kellgren--Lawrence scale; Karnofsky---Karnofsky Performance Status Scale; EQ-VAS---EuroQol Visual analogue scale; Eqol---EuroQol quality of life scale; CGI-S/C---The Clinical Global Impressions Scale; CFU---colony forming unit; AKSS---American Knee Society Score.

life-10-00094-t009_Table 9

###### 

Platelet-rich plasma (PRP) compared with control intervention as adjunct treatment for osteoarthritis (non-blinded RCTs).

  ------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
                             LOE   Type of Study   Exp          Cont         Follow-up   Control         Preparation Kit          LR/LP                  Plateletconcentration   Number of Inj.   PROM     K-L    Ref
  -------------------------- ----- --------------- ------------ ------------ ----------- --------------- ------------------------ ---------------------- ----------------------- ---------------- -------- ------ --------------------------
  Cerza et al.               I     2 arms          ACP 60(60)   60(60)       24 weeks    HA              ACP (Arthrex)            LP                     N/R                     4                WOMAC    1--3   \[[@B84-life-10-00094]\]

  Huang et al.               I     3 arms          40(40)       HA 40(40)\   12 months   HA\             N/R                      LP                     N/R                     4                WOMAC\   1--2   \[[@B77-life-10-00094]\]
                                                                CS 40(40)                CS                                                                                                       VAS             

  Raeissadat et al. (2015)   II    2 arms          PRP 87(77)   73(62)       12 months   HA              Rooyagen Kit             LR                     4.8 ± 1.80 × NPC        2                WOMAC\   1--4   \[[@B82-life-10-00094]\]
                                                                                                                                                                                                  SF-36           

  Rayegani et al.            I     2 arms          32(31)       33(31)       6 months    acetaminophen   Rooyagen kit             LR                     5.6 × NPC               2                WOMAC\   1--4   \[[@B64-life-10-00094]\]
                                                                                                                                                                                                  SF-36           

  Spakova et al.             II    2 arms          PRP 60       60           6 months    HA              Labofuge 400R, Heraeus   LR\                    680 ± 132 × 10^6^/mL    3                WOMAC\   1--3   \[[@B83-life-10-00094]\]
                                                                                                                                  6.4 ± 2.3 × 10^3^/µL                                            NRS-11          
  ------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

LOE---level of evidence; exp.---no. of patients receiving treatment in experimental group (no. of patients analyzed at final follow-up); cont.---no. of patients receiving treatment in control group (no. of patients analyzed at final follow-up); LR---leukocyte rich; LP---leukocyte poor; ROM---range of movement; PROM---patient related outcome measures; MRI---magnetic resonance imaging; VAS---visual analog scale; WOMAC---Western Ontario and McMaster Universities Osteoarthritis Index; SF-36---36-Item Short Form Survey; NRS-11---numerical rating scale.
